<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput xmlns:ns2="local" hits="10" offset="0" totalResults="42"><Filters total="48"><Filter label="Trial Technologies" name="trialTechnologies" total="47"><FilterOption id="762" count="28" label="Small molecule therapeutic"></FilterOption><FilterOption id="648" count="22" label="Intravenous formulation"></FilterOption><FilterOption id="740" count="20" label="Infusion"></FilterOption><FilterOption id="585" count="20" label="Oral formulation"></FilterOption><FilterOption id="746" count="19" label="Solution"></FilterOption><FilterOption id="761" count="17" label="Biological therapeutic"></FilterOption><FilterOption id="595" count="17" label="Tablet formulation"></FilterOption><FilterOption id="1647" count="14" label="Natural product"></FilterOption><FilterOption id="751" count="13" label="Film coating"></FilterOption><FilterOption id="573" count="13" label="Immunoglobulin-G"></FilterOption><FilterOption id="169" count="13" label="Monoclonal antibody humanized"></FilterOption><FilterOption id="898" count="11" label="Formulation powder"></FilterOption><FilterOption id="750" count="11" label="Freeze drying"></FilterOption><FilterOption id="85" count="11" label="Protein recombinant"></FilterOption><FilterOption id="647" count="7" label="Subcutaneous formulation"></FilterOption><FilterOption id="586" count="5" label="Capsule formulation"></FilterOption><FilterOption id="651" count="3" label="Intramuscular formulation"></FilterOption><FilterOption id="902" count="3" label="Orally disintegrating tablet"></FilterOption><FilterOption id="1652" count="3" label="Prodrug"></FilterOption><FilterOption id="630" count="3" label="Stereochemistry"></FilterOption><FilterOption id="589" count="3" label="Sustained release formulation"></FilterOption><FilterOption id="66" count="2" label="Antibiotic"></FilterOption><FilterOption id="894" count="2" label="Liquid formulation"></FilterOption><FilterOption id="80" count="2" label="Peptide"></FilterOption><FilterOption id="745" count="2" label="Suspension"></FilterOption><FilterOption id="127" count="1" label="Cell culture"></FilterOption><FilterOption id="128" count="1" label="Cell culture technique"></FilterOption><FilterOption id="166" count="1" label="Chimeric monoclonal antibody"></FilterOption><FilterOption id="641" count="1" label="Controlled release formulation"></FilterOption><FilterOption id="112" count="1" label="DNA technology"></FilterOption><FilterOption id="175" count="1" label="Drug combination"></FilterOption><FilterOption id="590" count="1" label="Enteric coated formulation"></FilterOption><FilterOption id="1663" count="1" label="Gel formulation"></FilterOption><FilterOption id="74" count="1" label="Glycoprotein"></FilterOption><FilterOption id="1263" count="1" label="Immuno-oncology"></FilterOption><FilterOption id="1646" count="1" label="Injectable controlled release formulation"></FilterOption><FilterOption id="598" count="1" label="Liposome formulation injectable"></FilterOption><FilterOption id="599" count="1" label="Nanoparticle formulation injectable"></FilterOption><FilterOption id="348" count="1" label="PEGylated formulation"></FilterOption><FilterOption id="742" count="1" label="Pellet"></FilterOption><FilterOption id="756" count="1" label="Pharmaceutical carrier"></FilterOption><FilterOption id="207" count="1" label="Protein conjugated"></FilterOption><FilterOption id="662" count="1" label="Quick release formulation"></FilterOption><FilterOption id="901" count="1" label="Recombinant enzyme"></FilterOption><FilterOption id="90" count="1" label="Steroid"></FilterOption><FilterOption id="558" count="1" label="Transdermal formulation"></FilterOption><FilterOption id="770" count="1" label="Transdermal gel formulation"></FilterOption></Filter><Filter label="Indications" name="indications" total="29"><FilterOption id="49" count="9" label="Breast tumor"></FilterOption><FilterOption id="3665" count="7" label="Metastatic non small cell lung cancer"></FilterOption><FilterOption id="1262" count="6" label="Non-small-cell lung cancer"></FilterOption><FilterOption id="3657" count="3" label="Metastatic breast cancer"></FilterOption><FilterOption id="224" count="3" label="Myocardial infarction"></FilterOption><FilterOption id="3114" count="2" label="Bipolar I disorder"></FilterOption><FilterOption id="57" count="2" label="Cardiovascular disease"></FilterOption><FilterOption id="4898" count="2" label="Major depressive disorder"></FilterOption><FilterOption id="65" count="2" label="Stroke"></FilterOption><FilterOption id="1584" count="2" label="Unstable angina"></FilterOption><FilterOption id="2399" count="1" label="Adenocarcinoma"></FilterOption><FilterOption id="17" count="1" label="Anemia"></FilterOption><FilterOption id="3644" count="1" label="Arterial thrombosis"></FilterOption><FilterOption id="1542" count="1" label="Atrial fibrillation"></FilterOption><FilterOption id="767" count="1" label="Colon tumor"></FilterOption><FilterOption id="93" count="1" label="Depression"></FilterOption><FilterOption id="1077" count="1" label="Embolism"></FilterOption><FilterOption id="750" count="1" label="Insomnia"></FilterOption><FilterOption id="836" count="1" label="Insulin dependent diabetes"></FilterOption><FilterOption id="3676" count="1" label="Ischemic stroke"></FilterOption><FilterOption id="1069" count="1" label="Metastasis"></FilterOption><FilterOption id="3669" count="1" label="Metastatic pancreas cancer"></FilterOption><FilterOption id="3666" count="1" label="Metastatic stomach cancer"></FilterOption><FilterOption id="1128" count="1" label="Neuroendocrine tumor"></FilterOption><FilterOption id="2860" count="1" label="Osteopenia"></FilterOption><FilterOption id="246" count="1" label="Osteoporosis"></FilterOption><FilterOption id="1845" count="1" label="Phlebothrombosis"></FilterOption><FilterOption id="1261" count="1" label="Small-cell lung cancer"></FilterOption><FilterOption id="307" count="1" label="Squamous cell carcinoma"></FilterOption></Filter><Filter label="Endpoint Index" name="trialEndpointIndex" total="100"><FilterOption id="8481" count="11" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8639" count="9" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8712" count="8" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8489" count="8" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8714" count="7" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="8524" count="6" label="Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"></FilterOption><FilterOption id="8508" count="6" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="8514" count="5" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8513" count="5" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8645" count="5" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of hematological toxicities"></FilterOption><FilterOption id="8996" count="4" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8555" count="4" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8505" count="4" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8516" count="4" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8641" count="4" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="8642" count="4" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicities (Upper and Lower)"></FilterOption><FilterOption id="8563" count="4" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="37159" count="3" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8713" count="3" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8722" count="3" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="8719" count="3" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8998" count="3" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="2623" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="2622" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2774" count="3" label="Coronary artery disease - Assessment of hospitalization"></FilterOption><FilterOption id="22595" count="3" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="8523" count="3" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8519" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption><FilterOption id="8522" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8640" count="3" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8643" count="3" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of pulmonary toxicities"></FilterOption><FilterOption id="8649" count="3" label="Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations"></FilterOption><FilterOption id="24178" count="3" label="Stroke - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="2859" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Non fatal myocardial infarction"></FilterOption><FilterOption id="2864" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2853" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="2981" count="2" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2957" count="2" label="Acute coronary syndrome - Assessment of Reperfusion/Revascularization"></FilterOption><FilterOption id="2871" count="2" label="Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Non-fatal Stroke"></FilterOption><FilterOption id="2952" count="2" label="Acute coronary syndrome - Assessment of hospitalization"></FilterOption><FilterOption id="9941" count="2" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)"></FilterOption><FilterOption id="9980" count="2" label="Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)"></FilterOption><FilterOption id="9954" count="2" label="Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="10025" count="2" label="Bipolar disorder - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8971" count="2" label="Breast tumor - Assessment of Hormone Levels"></FilterOption><FilterOption id="8749" count="2" label="Breast tumor - Assessment of Metastasis"></FilterOption><FilterOption id="8754" count="2" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8815" count="2" label="Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu"></FilterOption><FilterOption id="8759" count="2" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="37239" count="2" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of Efficacy"></FilterOption><FilterOption id="9103" count="2" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of Rate of Breast Conserving Surgery"></FilterOption><FilterOption id="9334" count="2" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of lymph nodes"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2503" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2609" count="2" label="Coronary artery disease - Assessment of Other Cardiovascular Events"></FilterOption><FilterOption id="2689" count="2" label="Coronary artery disease - Assessment of Reperfusion/Revascularization"></FilterOption><FilterOption id="2515" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"></FilterOption><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22597" count="2" label="End stage renal disease - Assessment of hospitalization - Assessment of Hospitalization Rates"></FilterOption><FilterOption id="23937" count="2" label="Hypercholesterolemia - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23944" count="2" label="Hypercholesterolemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="23072" count="2" label="Lipid metabolism disorder - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23079" count="2" label="Lipid metabolism disorder - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8629" count="2" label="Lung tumor - Assessment of Biomarkers"></FilterOption><FilterOption id="8644" count="2" label="Lung tumor - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="8549" count="2" label="Lung tumor - Assessment of Clinical Symptoms - Symptom assessment by lung cancer symptom scale (LCSS)"></FilterOption><FilterOption id="8504" count="2" label="Lung tumor - Assessment of Objective Response"></FilterOption><FilterOption id="8483" count="2" label="Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 1 year"></FilterOption><FilterOption id="8663" count="2" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8517" count="2" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate"></FilterOption><FilterOption id="8646" count="2" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of neurological complications"></FilterOption><FilterOption id="8502" count="2" label="Lung tumor - Assessment of Survival - Assessment of median survival"></FilterOption><FilterOption id="9153" count="2" label="Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria"></FilterOption><FilterOption id="23562" count="2" label="Menopause - Assessment of Therapy Related Outcomes - Assessment of response to cancer therapy"></FilterOption><FilterOption id="2980" count="1" label="Acute coronary syndrome - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="17356" count="1" label="Anemia - Assessment of adverse events"></FilterOption><FilterOption id="17294" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin response"></FilterOption><FilterOption id="9502" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events"></FilterOption><FilterOption id="9510" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"></FilterOption><FilterOption id="9438" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of all cause death"></FilterOption><FilterOption id="9519" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"></FilterOption><FilterOption id="9444" count="1" label="Atrial fibrillation - Assessments of Composite Endpoints"></FilterOption><FilterOption id="9948" count="1" label="Bipolar disorder - Assessment of Anxiety by Protocol Specified Scales - Assessment by Hamilton Anxiety Rating Scale (HAM-A)"></FilterOption><FilterOption id="10013" count="1" label="Bipolar disorder - Assessment of Cardiac Function"></FilterOption><FilterOption id="9942" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Quick Inventory Depressive Symptoms (QIDS)"></FilterOption><FilterOption id="10016" count="1" label="Bipolar disorder - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9932" count="1" label="Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)"></FilterOption><FilterOption id="10005" count="1" label="Bipolar disorder - Assessment of Physical Examination"></FilterOption><FilterOption id="9989" count="1" label="Bipolar disorder - Assessment of Sleep"></FilterOption><FilterOption id="10007" count="1" label="Bipolar disorder - Assessment of Vital Signs"></FilterOption><FilterOption id="10026" count="1" label="Bipolar disorder - Assessment of adverse events"></FilterOption><FilterOption id="9946" count="1" label="Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)"></FilterOption><FilterOption id="9042" count="1" label="Breast tumor - Anthropometric Assessments"></FilterOption><FilterOption id="8902" count="1" label="Breast tumor - Assessment of Biomarkers"></FilterOption><FilterOption id="8983" count="1" label="Breast tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="8745" count="1" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"></FilterOption><FilterOption id="8744" count="1" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8743" count="1" label="Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of local relapses"></FilterOption><FilterOption id="8740" count="1" label="Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption></Filter><Filter label="Trial Drug Phase Highest" name="trialDrugPhaseHighest" total="4"><FilterOption id="L" count="33" label="Launched"></FilterOption><FilterOption id="DX" count="2" label="Discontinued"></FilterOption><FilterOption id="C2" count="1" label="Phase 2 Clinical"></FilterOption><FilterOption id="C3" count="1" label="Phase 3 Clinical"></FilterOption></Filter><Filter label="Trial Company Sponsor" name="trialCompaniesSponsor" total="31"><FilterOption id="19446" count="11" label="Roche Holding AG"></FilterOption><FilterOption id="1042061" count="4" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="26178" count="3" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="18767" count="3" label="Pfizer Inc"></FilterOption><FilterOption id="1041586" count="2" label="Arnau de Vilanova Hospital"></FilterOption><FilterOption id="15358" count="2" label="Cephalon Inc"></FilterOption><FilterOption id="17810" count="2" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="1045513" count="2" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="1064840" count="1" label="Asociacion para el Progreso de la Oncologia en Malaga"></FilterOption><FilterOption id="14190" count="1" label="AstraZeneca plc"></FilterOption><FilterOption id="1013107" count="1" label="CNIC - Fundacion Centro National de Investigaciones Cardiovasculares Carlos III"></FilterOption><FilterOption id="1020322" count="1" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="1181926" count="1" label="Fundación Sociedad Española de Oncologia Médica"></FilterOption><FilterOption id="27053" count="1" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="1145220" count="1" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="28355" count="1" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1090124" count="1" label="Grupo de Investigación y Divulgación Oncológica"></FilterOption><FilterOption id="1047587" count="1" label="Hospital Arnau de Vilanova"></FilterOption><FilterOption id="1079172" count="1" label="Hospital General de Ciudad Real"></FilterOption><FilterOption id="1149835" count="1" label="Idorsia Ltd"></FilterOption><FilterOption id="17259" count="1" label="Ipsen"></FilterOption><FilterOption id="17961" count="1" label="Max Delbruck Centrum Fur Molekulare Medizin"></FilterOption><FilterOption id="1090120" count="1" label="NOVARTIS (SINGAPORE) PTE LTD"></FilterOption><FilterOption id="23137" count="1" label="Novartis AG"></FilterOption><FilterOption id="1144568" count="1" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="18614" count="1" label="Novo Nordisk A/S"></FilterOption><FilterOption id="1056256" count="1" label="Novotech (Australia) Pty Ltd"></FilterOption><FilterOption id="22006" count="1" label="Pharmacia &amp; Upjohn Inc"></FilterOption><FilterOption id="1126288" count="1" label="ROCHE (MALAYSIA) SDN. BHD"></FilterOption><FilterOption id="22487" count="1" label="The University of Hong Kong"></FilterOption><FilterOption id="25439" count="1" label="United Therapeutics Corp"></FilterOption></Filter><Filter label="Trial Recruitment Status" name="trialRecruitmentStatus" total="5"><FilterOption id="4" count="24" label="Completed"></FilterOption><FilterOption id="2" count="8" label="Recruiting"></FilterOption><FilterOption id="3" count="5" label="No longer recruiting"></FilterOption><FilterOption id="6" count="4" label="Terminated"></FilterOption><FilterOption id="5" count="1" label="Suspended"></FilterOption></Filter><Filter label="Trial Commercially Significant" name="trialIsCommerciallySignificant" total="2"><FilterOption id="YES" count="27" label="Yes"></FilterOption><FilterOption id="NO" count="15" label="No"></FilterOption></Filter><Filter label="Trial Indications Pioneer" name="trialIndicationsPioneer" total="6"><FilterOption id="224" count="3" label="Myocardial infarction"></FilterOption><FilterOption id="57" count="2" label="Cardiovascular disease"></FilterOption><FilterOption id="1584" count="2" label="Unstable angina"></FilterOption><FilterOption id="3676" count="1" label="Ischemic stroke"></FilterOption><FilterOption id="1261" count="1" label="Small-cell lung cancer"></FilterOption><FilterOption id="65" count="1" label="Stroke"></FilterOption></Filter><Filter label="Registry Id" name="trialRegistries" total="16"><FilterOption id="1000" count="41" label="CT.gov"></FilterOption><FilterOption id="1001" count="21" label="EudraCT"></FilterOption><FilterOption id="1012" count="6" label="CTRI"></FilterOption><FilterOption id="1030" count="4" label="RSRM CTR"></FilterOption><FilterOption id="1039" count="3" label="CDE"></FilterOption><FilterOption id="1011" count="2" label="ANZCTR"></FilterOption><FilterOption id="1019" count="2" label="DRKS"></FilterOption><FilterOption id="1009" count="2" label="HKClinicalTrials.com"></FilterOption><FilterOption id="1002" count="2" label="ISRCTN"></FilterOption><FilterOption id="1006" count="2" label="JapicCTI"></FilterOption><FilterOption id="1035" count="2" label="Singapore HSA CTR"></FilterOption><FilterOption id="1023" count="2" label="UKCRN"></FilterOption><FilterOption id="1004" count="2" label="WHO ICTRP"></FilterOption><FilterOption id="1021" count="1" label="NMRR"></FilterOption><FilterOption id="1038" count="1" label="PHRR"></FilterOption><FilterOption id="1003" count="1" label="UMIN"></FilterOption></Filter><Filter label="Trial Reason for Discontinuation" name="trialReasonForDiscontinuation" total="4"><FilterOption id="5" count="2" label="Patient Enrollment Issues"></FilterOption><FilterOption id="4" count="1" label="Other"></FilterOption><FilterOption id="7" count="1" label="Safety Issues"></FilterOption><FilterOption id="8" count="1" label="Sponsor/Business Decision"></FilterOption></Filter><Filter label="Active Controls" name="trialActiveControls" total="13"><FilterOption id="44383" count="2" label="carboplatin"></FilterOption><FilterOption id="2953" count="2" label="docetaxel"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="8047" count="1" label="bevacizumab"></FilterOption><FilterOption id="11961" count="1" label="erlotinib"></FilterOption><FilterOption id="3199" count="1" label="gemcitabine"></FilterOption><FilterOption id="10411" count="1" label="insulin aspart"></FilterOption><FilterOption id="2871" count="1" label="irinotecan"></FilterOption><FilterOption id="3803" count="1" label="paclitaxel"></FilterOption><FilterOption id="44314" count="1" label="tamoxifen"></FilterOption><FilterOption id="4577" count="1" label="topotecan"></FilterOption><FilterOption id="6386" count="1" label="trastuzumab"></FilterOption><FilterOption id="44375" count="1" label="warfarin"></FilterOption></Filter><Filter label="Exclusion Criteria Index" name="trialExclusionCriteriaIndex" total="100"><FilterOption id="5270" count="10" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="5132" count="8" label="Lung tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="6328" count="6" label="Breast tumor - Subjects with History of/Scheduled for Anti-neoplastic Therapy"></FilterOption><FilterOption id="5125" count="6" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with central nervous system metastases"></FilterOption><FilterOption id="5285" count="6" label="Lung tumor - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/scheduled for surgery"></FilterOption><FilterOption id="5282" count="6" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for radiation therapy"></FilterOption><FilterOption id="5345" count="6" label="Lung tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled to receive an investigational drug"></FilterOption><FilterOption id="6258" count="5" label="Breast tumor - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="6294" count="5" label="Breast tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6393" count="5" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="6377" count="5" label="Breast tumor - Subjects with history of/planned radiotherapy"></FilterOption><FilterOption id="20281" count="5" label="Lung tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="6756" count="5" label="Lung tumor - Subjects with History of/Scheduled for Other Cancer Therapies"></FilterOption><FilterOption id="5291" count="5" label="Lung tumor - Subjects with History of/Scheduled for Other Treatments"></FilterOption><FilterOption id="5349" count="5" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects unable/unwilling to comply with protocol requirements"></FilterOption><FilterOption id="6246" count="4" label="Breast tumor - Subjects by disease severity - Metastatic/TNM Stage IV Breast Cancer"></FilterOption><FilterOption id="6272" count="4" label="Breast tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="6331" count="4" label="Breast tumor - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of/scheduled for chemotherapy"></FilterOption><FilterOption id="6217" count="4" label="Breast tumor - Subjects with Other forms of Breast Cancer - Subjects with bilateral breast cancer"></FilterOption><FilterOption id="5128" count="4" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases/disorders"></FilterOption><FilterOption id="5193" count="4" label="Lung tumor - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="6228" count="3" label="Breast tumor - Subjects by disease severity - Subjects with lobular carcinoma in situ (LCIS)"></FilterOption><FilterOption id="6253" count="3" label="Breast tumor - Subjects with Co-morbid Conditions - Subjects with central nervous system diseases"></FilterOption><FilterOption id="6252" count="3" label="Breast tumor - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="1662" count="3" label="Coronary artery disease - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with congestive heart failure (Killip class II-IV/NYHA Class II-IV)/Failure of the right ventricle/Decompensated heart failure"></FilterOption><FilterOption id="17519" count="3" label="End stage renal disease - Subjects co-morbid with cardiovascular diseases/disorders"></FilterOption><FilterOption id="17522" count="3" label="End stage renal disease - Subjects co-morbid with hepatobiliary disorders/diseases"></FilterOption><FilterOption id="17553" count="3" label="End stage renal disease - Subjects with Contraindications to Study Procedure"></FilterOption><FilterOption id="5365" count="3" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="5236" count="3" label="Lung tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="6757" count="3" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects with history of/current participation in other clinical trials"></FilterOption><FilterOption id="5322" count="3" label="Lung tumor - Subjects with Therapy Associated Toxicity"></FilterOption><FilterOption id="2064" count="2" label="Acute coronary syndrome - Subjects co-morbid with Cerebrovascular Disorders/Diseases - Subjects co-morbid with hemorrhagic stroke"></FilterOption><FilterOption id="2003" count="2" label="Acute coronary syndrome - Subjects co-morbid with heart disorders/diseases - Heart failure (Killip class II-IV/NYHA Class II-IV)"></FilterOption><FilterOption id="2031" count="2" label="Acute coronary syndrome - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="2163" count="2" label="Acute coronary syndrome - Subjects with Abnormal Laboratory Findings - Lipid profile"></FilterOption><FilterOption id="2162" count="2" label="Acute coronary syndrome - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="2206" count="2" label="Acute coronary syndrome - Subjects with History of Other Procedure/Intervention - Renal dialysis"></FilterOption><FilterOption id="2155" count="2" label="Acute coronary syndrome - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with CABG (Coronary artery bypass graft) surgery"></FilterOption><FilterOption id="2159" count="2" label="Acute coronary syndrome - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with history of/schdeuled for percutaneous transluminal coronary angioplasty (PTCA)"></FilterOption><FilterOption id="7430" count="2" label="Bipolar disorder - Subjects co-morbid with Psychiatric Disease/Disorder - Subjects co-morbid with psychotic disorders"></FilterOption><FilterOption id="7436" count="2" label="Bipolar disorder - Subjects co-morbid with Psychiatric Disease/Disorder - Subjects with substance related disorders"></FilterOption><FilterOption id="7427" count="2" label="Bipolar disorder - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="7439" count="2" label="Bipolar disorder - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="7470" count="2" label="Bipolar disorder - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="7419" count="2" label="Bipolar disorder - Subjects with Protocol Specified Clinical Manifestations - Subjects with psychosis"></FilterOption><FilterOption id="6227" count="2" label="Breast tumor - Subjects by disease severity - Subjects with ductal carcinoma in situ (DCIS)"></FilterOption><FilterOption id="6259" count="2" label="Breast tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="6260" count="2" label="Breast tumor - Subjects co-morbid with gastrointestinal diseases/disorders"></FilterOption><FilterOption id="6913" count="2" label="Breast tumor - Subjects with Complications Cancer Therapy"></FilterOption><FilterOption id="20289" count="2" label="Breast tumor - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy - Subjects with history of biologic therapy"></FilterOption><FilterOption id="6317" count="2" label="Breast tumor - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients - Subjects with hypersensitivity/contraindications to immunomodulators"></FilterOption><FilterOption id="1667" count="2" label="Coronary artery disease - Subjects co-morbid with cardiovascular diseases/disorders - Severe left ventricular dysfunction /abnormal left ventricular ejection fraction"></FilterOption><FilterOption id="1860" count="2" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal lipid profile / values"></FilterOption><FilterOption id="1858" count="2" label="Coronary artery disease - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"></FilterOption><FilterOption id="5588" count="2" label="Coronary artery disease - Subjects with Co-morbid Conditions - Subjects co-morbid with cerebrovascular/CNS disorder"></FilterOption><FilterOption id="1851" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Diagnostic/Therapeutic Procedures - Percutaneous coronary intervention (PCI) - Angioplasty"></FilterOption><FilterOption id="1846" count="2" label="Coronary artery disease - Subjects with History of/Scheduled for Intervention/Surgery - Subjects with CABG (Coronary artery bypass graft) surgery"></FilterOption><FilterOption id="1701" count="2" label="Coronary artery disease - Subjects with History of/Scheduled to Receive Therapy - Subjects on hemodialysis"></FilterOption><FilterOption id="17524" count="2" label="End stage renal disease - Subjects co-morbid with Endocrine/Metabolic Disorders"></FilterOption><FilterOption id="17531" count="2" label="End stage renal disease - Subjects co-morbid with infections"></FilterOption><FilterOption id="17518" count="2" label="End stage renal disease - Subjects co-morbid with neurological disorders/diseases"></FilterOption><FilterOption id="17510" count="2" label="End stage renal disease - Subjects co-morbid with renal disease/disorder - Subjects with chronic kidney disease"></FilterOption><FilterOption id="17533" count="2" label="End stage renal disease - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="17541" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy"></FilterOption><FilterOption id="17551" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Intervention/Surgery"></FilterOption><FilterOption id="17537" count="2" label="End stage renal disease - Subjects with History of/Scheduled for Renal Replacement Therapy - Subjects with protocol specified dialysis related criteria"></FilterOption><FilterOption id="17517" count="2" label="End stage renal disease - Subjects with Renal Function Outside of Protocol Specified Limits - Subjects with creatinine level outside of protocol specified limits"></FilterOption><FilterOption id="18583" count="2" label="Hypercholesterolemia - Immunocompromised Subjects - Subjects immunocompromized with HIV infection"></FilterOption><FilterOption id="18586" count="2" label="Hypercholesterolemia - Subjects co-morbid with Cerebrovascular Disorders/Diseases"></FilterOption><FilterOption id="18579" count="2" label="Hypercholesterolemia - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with heart failure"></FilterOption><FilterOption id="18576" count="2" label="Hypercholesterolemia - Subjects co-morbid with heart disorders/diseases"></FilterOption><FilterOption id="18575" count="2" label="Hypercholesterolemia - Subjects co-morbid with hypertension"></FilterOption><FilterOption id="18582" count="2" label="Hypercholesterolemia - Subjects co-morbid with infections"></FilterOption><FilterOption id="18573" count="2" label="Hypercholesterolemia - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="18596" count="2" label="Hypercholesterolemia - Subjects with Abnormal Laboratory Findings - Abnormal liver function test"></FilterOption><FilterOption id="18597" count="2" label="Hypercholesterolemia - Subjects with Abnormal Laboratory Findings - Subjects with abnormal renal function tests"></FilterOption><FilterOption id="18595" count="2" label="Hypercholesterolemia - Subjects with Abnormal Laboratory Findings"></FilterOption><FilterOption id="18588" count="2" label="Hypercholesterolemia - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="18560" count="2" label="Hypercholesterolemia - Subjects with Dyslipidemia - Subjects with abnormal LDL levels"></FilterOption><FilterOption id="18581" count="2" label="Hypercholesterolemia - Subjects with History of/Active Malignancy/Cancer"></FilterOption><FilterOption id="18601" count="2" label="Hypercholesterolemia - Subjects with History of/Current Use of a Prohibited Medication"></FilterOption><FilterOption id="18602" count="2" label="Hypercholesterolemia - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="17716" count="2" label="Lipid metabolism disorder - Immunocompromised Subjects - Subjects immunocompromized with HIV infection"></FilterOption><FilterOption id="17719" count="2" label="Lipid metabolism disorder - Subjects co-morbid with Cerebrovascular Disorders/Diseases"></FilterOption><FilterOption id="17718" count="2" label="Lipid metabolism disorder - Subjects co-morbid with Psychiatric Disease/Disorder"></FilterOption><FilterOption id="17712" count="2" label="Lipid metabolism disorder - Subjects co-morbid with cardiovascular diseases/disorders - Subjects co-morbid with heart failure"></FilterOption><FilterOption id="17709" count="2" label="Lipid metabolism disorder - Subjects co-morbid with heart disorders/diseases"></FilterOption><FilterOption id="17708" count="2" label="Lipid metabolism disorder - Subjects co-morbid with hypertension"></FilterOption><FilterOption id="17715" count="2" label="Lipid metabolism disorder - Subjects co-morbid with infections"></FilterOption><FilterOption id="5347" count="2" label="Lung tumor - Protocol Specified Other Exclusion Criteria - Subjects with abnormal laboratory values"></FilterOption><FilterOption id="5139" count="2" label="Lung tumor - Subjects co-morbid with Respiratory Diseases/Disorders - Subjects co-morbid with pulmonary diseases/disorders"></FilterOption><FilterOption id="5168" count="2" label="Lung tumor - Subjects co-morbid with endocrine/metabolic diseases/disorders"></FilterOption><FilterOption id="20282" count="2" label="Lung tumor - Subjects co-morbid with inflammatory disorders"></FilterOption><FilterOption id="5122" count="2" label="Lung tumor - Subjects with Evidence of Metastasis - Subjects with symptomatic/uncontrolled metastases"></FilterOption><FilterOption id="5121" count="2" label="Lung tumor - Subjects with Evidence of Metastasis"></FilterOption><FilterOption id="5331" count="2" label="Lung tumor - Subjects with Specific Grade of Toxicity - Subjects with grade 2 toxicity (moderate)"></FilterOption><FilterOption id="18692" count="2" label="Stroke - Subjects with Hypersensitivity/Contraindications to Drugs/Excipients"></FilterOption><FilterOption id="11881" count="1" label="Anemia - Protocol Specified Other Exclusion Criteria - Protocol specified exclusion criteria for females"></FilterOption><FilterOption id="11825" count="1" label="Anemia - Subjects with Co-morbid Conditions - Subjects co-morbid with hematological disease/disorders"></FilterOption></Filter><Filter label="Trial Date Enrollment End By Month" name="trialDateEnrollmentEndByMonth" total="17"><FilterOption count="2" label="200807"></FilterOption><FilterOption count="2" label="200903"></FilterOption><FilterOption count="2" label="201603"></FilterOption><FilterOption count="1" label="200801"></FilterOption><FilterOption count="1" label="200812"></FilterOption><FilterOption count="1" label="200907"></FilterOption><FilterOption count="1" label="201001"></FilterOption><FilterOption count="1" label="201012"></FilterOption><FilterOption count="1" label="201106"></FilterOption><FilterOption count="1" label="201202"></FilterOption><FilterOption count="1" label="201302"></FilterOption><FilterOption count="1" label="201310"></FilterOption><FilterOption count="1" label="201507"></FilterOption><FilterOption count="1" label="201508"></FilterOption><FilterOption count="1" label="201512"></FilterOption><FilterOption count="1" label="201611"></FilterOption><FilterOption count="1" label="201811"></FilterOption></Filter><Filter label="Funder Type" name="trialFunderType" total="4"><FilterOption id="CMP" count="34" label="Company"></FilterOption><FilterOption id="ACA" count="13" label="Academic"></FilterOption><FilterOption id="GOV" count="1" label="Government"></FilterOption><FilterOption id="OTH" count="1" label="Others"></FilterOption></Filter><Filter label="Trial Region" name="trialRegions" total="10"><FilterOption id="NSWE" count="42" label="Northern, Southern &amp; Western Europe"></FilterOption><FilterOption id="AUNZ" count="15" label="Australia &amp; New Zealand"></FilterOption><FilterOption id="EEUR" count="15" label="Eastern Europe"></FilterOption><FilterOption id="USCA" count="15" label="US &amp; Canada"></FilterOption><FilterOption id="SOAM" count="14" label="South America"></FilterOption><FilterOption id="MENA" count="13" label="Middle East &amp; North Africa"></FilterOption><FilterOption id="EAPO" count="12" label="East Asia &amp; Pacific Ocean"></FilterOption><FilterOption id="SOCA" count="11" label="Southern &amp; Central Asia"></FilterOption><FilterOption id="CSAF" count="10" label="Central &amp; Southern Africa"></FilterOption><FilterOption id="CAAC" count="7" label="Central America &amp; Caribbean"></FilterOption></Filter><Filter label="Patient Segment Index" name="trialPatientSegmentIndex" total="97"><FilterOption id="3634" count="10" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer"></FilterOption><FilterOption id="3617" count="10" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="10295" count="9" label="Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer"></FilterOption><FilterOption id="3623" count="8" label="Lung tumor - Subjects with Advanced Stage Lung Cancer"></FilterOption><FilterOption id="3936" count="5" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="3952" count="5" label="Breast tumor - Subjects with Locally Advanced Breast Cancer"></FilterOption><FilterOption id="12845" count="5" label="Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification"></FilterOption><FilterOption id="7877" count="5" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer"></FilterOption><FilterOption id="3950" count="4" label="Breast tumor - Subjects with Early Stage Breast Cancer"></FilterOption><FilterOption id="3955" count="4" label="Breast tumor - Subjects with Resectable/Operable Breast Cancer"></FilterOption><FilterOption id="3944" count="4" label="Breast tumor - Subjects with Stage II Breast Cancer"></FilterOption><FilterOption id="3650" count="4" label="Lung tumor - Subjects with Recurrent/Relapsed Lung Cancer"></FilterOption><FilterOption id="12053" count="4" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="3970" count="3" label="Breast tumor - Others - Subjects with node positive breast cancer"></FilterOption><FilterOption id="3954" count="3" label="Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer"></FilterOption><FilterOption id="10129" count="3" label="Lung tumor - Subjects with EGFR Positive Lung Cancer"></FilterOption><FilterOption id="3647" count="3" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="343" count="2" label="Acute coronary syndrome - Subjects at risk of developing disease - Hyperlipidemia"></FilterOption><FilterOption id="341" count="2" label="Acute coronary syndrome - Subjects at risk of developing disease"></FilterOption><FilterOption id="7290" count="2" label="Bipolar disorder - Subjects with Bipolar I Disorder"></FilterOption><FilterOption id="3937" count="2" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="3931" count="2" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="3943" count="2" label="Breast tumor - Subjects with Stage I Breast Cancer"></FilterOption><FilterOption id="3946" count="2" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIA Breast cancer"></FilterOption><FilterOption id="3945" count="2" label="Breast tumor - Subjects with Stage III Breast Cancer"></FilterOption><FilterOption id="3956" count="2" label="Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer"></FilterOption><FilterOption id="369" count="2" label="Coronary artery disease - Subjects on /Indicated for/History of Cardiovascular Therapy"></FilterOption><FilterOption id="226" count="2" label="Coronary artery disease - Subjects with High Cardiovascular Risk Profile - Hyperlipidemia/dyslipidemia"></FilterOption><FilterOption id="224" count="2" label="Coronary artery disease - Subjects with High Cardiovascular Risk Profile"></FilterOption><FilterOption id="7700" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="7760" count="2" label="Hypercholesterolemia - Subjects with Familial Hypercholesterolemia (Fredrickson Type IIa Hyperlipoproteinemia) - Subjects with heterozygous familial hypercholesterolemia"></FilterOption><FilterOption id="7772" count="2" label="Hypercholesterolemia - Subjects with Increased LDL-cholesterol Levels"></FilterOption><FilterOption id="7756" count="2" label="Hypercholesterolemia - Subjects with Primary Hypercholesterolemia"></FilterOption><FilterOption id="7771" count="2" label="Hypercholesterolemia - Subjects with Reduced HDL-cholesterol Levels"></FilterOption><FilterOption id="7783" count="2" label="Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with diabetes mellitus as a risk factor for coronary heart disease"></FilterOption><FilterOption id="7782" count="2" label="Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease - Subjects with smoking"></FilterOption><FilterOption id="7780" count="2" label="Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease"></FilterOption><FilterOption id="7787" count="2" label="Hypercholesterolemia - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction"></FilterOption><FilterOption id="11305" count="2" label="Lipid metabolism disorder - Subjects with Familial Hypercholesterolemia (Frederickson type IIa Hyperlipoproteinemia) - Subjects with heterozygous familial hypercholesterolemia"></FilterOption><FilterOption id="11314" count="2" label="Lipid metabolism disorder - Subjects with Increased LDL-cholesterol Levels"></FilterOption><FilterOption id="11301" count="2" label="Lipid metabolism disorder - Subjects with Primary Hypercholesterolemia"></FilterOption><FilterOption id="11313" count="2" label="Lipid metabolism disorder - Subjects with Reduced HDL-cholesterol Levels"></FilterOption><FilterOption id="11322" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD) - Subjects with diabetes mellitus"></FilterOption><FilterOption id="11321" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD) - Subjects with smoking"></FilterOption><FilterOption id="11319" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease(CHD)"></FilterOption><FilterOption id="11326" count="2" label="Lipid metabolism disorder - Subjects with comorbid conditions - Subjects with renal disorders/diseases/dysfunction"></FilterOption><FilterOption id="3637" count="2" label="Lung tumor - Subjects with Unresectable/In-operable Lung Cancer"></FilterOption><FilterOption id="11612" count="2" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal Subjects"></FilterOption><FilterOption id="11621" count="2" label="Menopause - Subjects with comorbid conditions - Subjects with Cancer"></FilterOption><FilterOption id="11654" count="2" label="Stroke - Subjects at risk of developing disease - Subjects with diabetes mellitus"></FilterOption><FilterOption id="11653" count="2" label="Stroke - Subjects with Cardiovascular Risk - Subjects with dyslipidemia"></FilterOption><FilterOption id="11652" count="2" label="Stroke - Subjects with Cardiovascular Risk"></FilterOption><FilterOption id="11658" count="2" label="Stroke - Subjects with Other Heart Diseases"></FilterOption><FilterOption id="373" count="1" label="Acute coronary syndrome - Subjects with History of Treatment"></FilterOption><FilterOption id="7512" count="1" label="Anemia - Subjects with specific disease - Subjects with Cancer/Cancer Chemotherapy Induced Anemia"></FilterOption><FilterOption id="7364" count="1" label="Atrial fibrillation - Subjects with Additional Risk Factor for Thromboembolic Events"></FilterOption><FilterOption id="3932" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Progesterone receptor positive (PR+) breast cancer"></FilterOption><FilterOption id="3930" count="1" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer"></FilterOption><FilterOption id="3966" count="1" label="Breast tumor - Subjects with Relapsed/Recurrent Breast cancer"></FilterOption><FilterOption id="3947" count="1" label="Breast tumor - Subjects with Stage III Breast Cancer - TNM stage IIIB Breast cancer"></FilterOption><FilterOption id="12005" count="1" label="Breast tumor - Subjects with invasive breast cancer"></FilterOption><FilterOption id="3969" count="1" label="Breast tumor - Subjects with node negative breast cancer"></FilterOption><FilterOption id="12029" count="1" label="Cancer supportive care - Cancer-Hematological Complications"></FilterOption><FilterOption id="9010" count="1" label="Cancer supportive care - Solid tumor subjects for supportive care"></FilterOption><FilterOption id="3814" count="1" label="Colorectal tumor - Subjects with Colon Cancer"></FilterOption><FilterOption id="3823" count="1" label="Colorectal tumor - Subjects with TNM stage III/Dukes C Colorectal Cancer"></FilterOption><FilterOption id="243" count="1" label="Coronary artery disease - Subjects with Abnormal Angiographic Findings"></FilterOption><FilterOption id="174" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Acute onset/new onset myocardial infarction (MI)"></FilterOption><FilterOption id="176" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - Non ST elevation myocardial infarction (NSTEMI)"></FilterOption><FilterOption id="178" count="1" label="Coronary artery disease - Subjects with Unstable Coronary Artery Disease - ST elevation myocardial infarction (STEMI)"></FilterOption><FilterOption id="7449" count="1" label="Depression - Subjects with Major Depressive Disorder"></FilterOption><FilterOption id="7458" count="1" label="Depression - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="7708" count="1" label="End stage renal disease - Subjects with Diabetes/Diabetic Nephropathy"></FilterOption><FilterOption id="10257" count="1" label="Heart arrhythmia - Subjects with Additional Risk Factor for Thromboembolic Events"></FilterOption><FilterOption id="7798" count="1" label="Hypercholesterolemia - Subjects Refractory/Intolerant to Lipid Lowering Therapy - Subjects refractory/intolerant to statin therapy"></FilterOption><FilterOption id="11084" count="1" label="Insomnia - Elderly Subjects"></FilterOption><FilterOption id="11329" count="1" label="Lipid metabolism disorder - Subjects Refractory to Statin Therapy"></FilterOption><FilterOption id="7486" count="1" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with squamous cell lung cancer"></FilterOption><FilterOption id="3618" count="1" label="Lung tumor - Subjects with Small Cell (Oat Cell) Lung Cancer (SCLC)"></FilterOption><FilterOption id="14654" count="1" label="Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(GOF)"></FilterOption><FilterOption id="14735" count="1" label="Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(TK_domain)"></FilterOption><FilterOption id="16353" count="1" label="Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(exon21)"></FilterOption><FilterOption id="14655" count="1" label="Lung tumor - Subjects with gene variants - EGFR_HUMAN_delex19"></FilterOption><FilterOption id="14896" count="1" label="Lung tumor - Subjects with gene variants - HRAS_HUMAN_Mutation"></FilterOption><FilterOption id="11624" count="1" label="Menopause - Subjects with History of/Scheduled for drug Therapy"></FilterOption><FilterOption id="9943" count="1" label="Neuroendocrine tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="9903" count="1" label="Neuroendocrine tumor - Subjects with Well Differentiated (Low &amp; Intermediate-grade) NET"></FilterOption><FilterOption id="7665" count="1" label="Osteoporosis - Subjects at risk of developing disease - Women at risk of developing osteoporosis"></FilterOption><FilterOption id="8073" count="1" label="Pancreas tumor - Subjects with Advanced/Metastatic Pancreatic Cancer"></FilterOption><FilterOption id="8084" count="1" label="Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer - TNM Stage III pancreatic cancer"></FilterOption><FilterOption id="8072" count="1" label="Pancreas tumor - Subjects with Locally Advanced Pancreatic Cancer"></FilterOption><FilterOption id="8085" count="1" label="Pancreas tumor - Subjects with Pancreatic Endocrine Tumors (PETs) - Subjects with pancreatic neuroendocrine tumor (NET)"></FilterOption><FilterOption id="8079" count="1" label="Pancreas tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="8010" count="1" label="Stomach tumor - Subjects with Advanced/Metastatic Gastric Cancer"></FilterOption><FilterOption id="11650" count="1" label="Stroke - Subjects with comorbid conditions - Subjects with Atrial Fibrillation"></FilterOption><FilterOption id="7332" count="1" label="Thrombosis - Subjects with comorbid conditions - Subjects co-morbid with active malignancy/tumors"></FilterOption><FilterOption id="7327" count="1" label="Thrombosis - Subjects with disease related complications - Subjects with thromboembolic manifestations"></FilterOption></Filter><Filter label="Primary Completion Filter by Month" name="trialPrimaryCompletionDateByMonth" total="34"><FilterOption count="2" label="200912"></FilterOption><FilterOption count="2" label="201008"></FilterOption><FilterOption count="2" label="201909"></FilterOption><FilterOption count="1" label="200509"></FilterOption><FilterOption count="1" label="200512"></FilterOption><FilterOption count="1" label="200708"></FilterOption><FilterOption count="1" label="200812"></FilterOption><FilterOption count="1" label="200906"></FilterOption><FilterOption count="1" label="200909"></FilterOption><FilterOption count="1" label="200910"></FilterOption><FilterOption count="1" label="200911"></FilterOption><FilterOption count="1" label="201007"></FilterOption><FilterOption count="1" label="201011"></FilterOption><FilterOption count="1" label="201103"></FilterOption><FilterOption count="1" label="201112"></FilterOption><FilterOption count="1" label="201203"></FilterOption><FilterOption count="1" label="201210"></FilterOption><FilterOption count="1" label="201211"></FilterOption><FilterOption count="1" label="201304"></FilterOption><FilterOption count="1" label="201310"></FilterOption><FilterOption count="1" label="201312"></FilterOption><FilterOption count="1" label="201406"></FilterOption><FilterOption count="1" label="201503"></FilterOption><FilterOption count="1" label="201506"></FilterOption><FilterOption count="1" label="201601"></FilterOption><FilterOption count="1" label="201607"></FilterOption><FilterOption count="1" label="201703"></FilterOption><FilterOption count="1" label="201704"></FilterOption><FilterOption count="1" label="201706"></FilterOption><FilterOption count="1" label="201907"></FilterOption><FilterOption count="1" label="201911"></FilterOption><FilterOption count="1" label="202007"></FilterOption><FilterOption count="1" label="202011"></FilterOption><FilterOption count="1" label="202105"></FilterOption></Filter><Filter label="Trial Country" name="trialCountries" total="89"><FilterOption id="ES" count="42" label="Spain"></FilterOption><FilterOption id="FR" count="17" label="France"></FilterOption><FilterOption id="IT" count="17" label="Italy"></FilterOption><FilterOption id="AU" count="15" label="Australia"></FilterOption><FilterOption id="PL" count="15" label="Poland"></FilterOption><FilterOption id="CA" count="13" label="Canada"></FilterOption><FilterOption id="DE" count="13" label="Germany"></FilterOption><FilterOption id="BR" count="12" label="Brazil"></FilterOption><FilterOption id="HU" count="12" label="Hungary"></FilterOption><FilterOption id="AR" count="11" label="Argentina"></FilterOption><FilterOption id="IN" count="11" label="India"></FilterOption><FilterOption id="GB" count="11" label="UK"></FilterOption><FilterOption id="CZ" count="10" label="Czech Republic"></FilterOption><FilterOption id="NL" count="10" label="Netherlands"></FilterOption><FilterOption id="RO" count="10" label="Romania"></FilterOption><FilterOption id="RU" count="10" label="Russian Federation"></FilterOption><FilterOption id="ZA" count="10" label="South Africa"></FilterOption><FilterOption id="TR" count="10" label="Turkey"></FilterOption><FilterOption id="US" count="10" label="US"></FilterOption><FilterOption id="BG" count="9" label="Bulgaria"></FilterOption><FilterOption id="FI" count="9" label="Finland"></FilterOption><FilterOption id="RS" count="9" label="Serbia"></FilterOption><FilterOption id="SK" count="9" label="Slovakia"></FilterOption><FilterOption id="SE" count="9" label="Sweden"></FilterOption><FilterOption id="CH" count="9" label="Switzerland"></FilterOption><FilterOption id="TW" count="9" label="Taiwan"></FilterOption><FilterOption id="BE" count="8" label="Belgium"></FilterOption><FilterOption id="CN" count="8" label="China"></FilterOption><FilterOption id="DK" count="8" label="Denmark"></FilterOption><FilterOption id="IL" count="8" label="Israel"></FilterOption><FilterOption id="KR" count="8" label="South Korea"></FilterOption><FilterOption id="HR" count="7" label="Croatia"></FilterOption><FilterOption id="HK" count="7" label="Hong Kong"></FilterOption><FilterOption id="MX" count="7" label="Mexico"></FilterOption><FilterOption id="TH" count="7" label="Thailand"></FilterOption><FilterOption id="UA" count="7" label="Ukraine"></FilterOption><FilterOption id="CL" count="6" label="Chile"></FilterOption><FilterOption id="CO" count="6" label="Colombia"></FilterOption><FilterOption id="EG" count="6" label="Egypt"></FilterOption><FilterOption id="GR" count="6" label="Greece"></FilterOption><FilterOption id="IE" count="6" label="Ireland"></FilterOption><FilterOption id="NZ" count="6" label="New Zealand"></FilterOption><FilterOption id="PT" count="6" label="Portugal"></FilterOption><FilterOption id="AT" count="5" label="Austria"></FilterOption><FilterOption id="EE" count="5" label="Estonia"></FilterOption><FilterOption id="JP" count="5" label="Japan"></FilterOption><FilterOption id="NO" count="5" label="Norway"></FilterOption><FilterOption id="PE" count="5" label="Peru"></FilterOption><FilterOption id="PH" count="5" label="Philippines"></FilterOption><FilterOption id="SI" count="5" label="Slovenia"></FilterOption><FilterOption id="BA" count="4" label="Bosnia and Herzegovina"></FilterOption><FilterOption id="LT" count="4" label="Lithuania"></FilterOption><FilterOption id="MY" count="4" label="Malaysia"></FilterOption><FilterOption id="EC" count="3" label="Ecuador"></FilterOption><FilterOption id="LB" count="3" label="Lebanon"></FilterOption><FilterOption id="PK" count="3" label="Pakistan"></FilterOption><FilterOption id="SA" count="3" label="Saudi Arabia"></FilterOption><FilterOption id="SG" count="3" label="Singapore"></FilterOption><FilterOption id="VE" count="3" label="Venezuela"></FilterOption><FilterOption id="DZ" count="2" label="Algeria"></FilterOption><FilterOption id="BH" count="2" label="Bahrain"></FilterOption><FilterOption id="CR" count="2" label="Costa Rica"></FilterOption><FilterOption id="X5" count="2" label="Europe"></FilterOption><FilterOption id="GT" count="2" label="Guatemala"></FilterOption><FilterOption id="ID" count="2" label="Indonesia"></FilterOption><FilterOption id="KW" count="2" label="Kuwait"></FilterOption><FilterOption id="LU" count="2" label="Luxembourg"></FilterOption><FilterOption id="MA" count="2" label="Morocco"></FilterOption><FilterOption id="PR" count="2" label="Puerto Rico"></FilterOption><FilterOption id="QA" count="2" label="Qatar"></FilterOption><FilterOption id="AE" count="2" label="United Arab Emirates"></FilterOption><FilterOption id="UY" count="2" label="Uruguay"></FilterOption><FilterOption id="VN" count="2" label="Vietnam"></FilterOption><FilterOption id="X0" count="1" label="Africa"></FilterOption><FilterOption id="AL" count="1" label="Albania"></FilterOption><FilterOption id="X2" count="1" label="Asia"></FilterOption><FilterOption id="DO" count="1" label="Dominican Republic"></FilterOption><FilterOption id="SV" count="1" label="El Salvador"></FilterOption><FilterOption id="GE" count="1" label="Georgia"></FilterOption><FilterOption id="IS" count="1" label="Iceland"></FilterOption><FilterOption id="LV" count="1" label="Latvia"></FilterOption><FilterOption id="MT" count="1" label="Malta"></FilterOption><FilterOption id="MD" count="1" label="Moldova, Republic of"></FilterOption><FilterOption id="ME" count="1" label="Montenegro"></FilterOption><FilterOption id="KP" count="1" label="North Korea"></FilterOption><FilterOption id="PA" count="1" label="Panama"></FilterOption><FilterOption id="XE" count="1" label="South America"></FilterOption><FilterOption id="TT" count="1" label="Trinidad and Tobago"></FilterOption><FilterOption id="TN" count="1" label="Tunisia"></FilterOption></Filter><Filter label="Trial Patient Selection" name="trialTermsPatientSelection" total="9"><FilterOption id="EAAAD" count="40" label="Aged Adults (65-79 yrs)"></FilterOption><FilterOption id="EAMAA" count="39" label="Middle-aged Adults (45-64 yrs)"></FilterOption><FilterOption id="EAYAD" count="39" label="Young Adults (18-44 yrs)"></FilterOption><FilterOption id="EAELD" count="35" label="Elderly Adults (80 and over)"></FilterOption><FilterOption id="EGFEM" count="7" label="Female"></FilterOption><FilterOption id="ECASI" count="1" label="Asian Ancestry"></FilterOption><FilterOption id="ECEUR" count="1" label="European Ancestry"></FilterOption><FilterOption id="ECJAP" count="1" label="Japanese Ancestry"></FilterOption><FilterOption id="EGMAL" count="1" label="Male"></FilterOption></Filter><Filter label="Trial Terms Design" name="trialTermsDesign" total="19"><FilterOption id="SSTINV" count="33" label="Interventional"></FilterOption><FilterOption id="SIPTRE" count="30" label="Treatment"></FilterOption><FilterOption id="SIMOPN" count="24" label="Open Label"></FilterOption><FilterOption id="SISPRL" count="18" label="Parallel Assignment"></FilterOption><FilterOption id="SIARND" count="17" label="Randomized"></FilterOption><FilterOption id="SISSNG" count="13" label="Single Group Assignment"></FilterOption><FilterOption id="SICACT" count="10" label="Active Control"></FilterOption><FilterOption id="SIANON" count="10" label="Non-Randomized"></FilterOption><FilterOption id="SSTOBS" count="9" label="Observational"></FilterOption><FilterOption id="SICNOC" count="8" label="No Control"></FilterOption><FilterOption id="SIMMBD" count="7" label="Multiple Blind"></FilterOption><FilterOption id="SICPLC" count="6" label="Placebo Control"></FilterOption><FilterOption id="SOSCOH" count="5" label="Cohort"></FilterOption><FilterOption id="SOTPRO" count="5" label="Prospective"></FilterOption><FilterOption id="SIPPRE" count="3" label="Prevention"></FilterOption><FilterOption id="SOTRET" count="3" label="Retrospective"></FilterOption><FilterOption id="SODLNG" count="2" label="Longitudinal"></FilterOption><FilterOption id="SOSCSC" count="1" label="Case Control"></FilterOption><FilterOption id="SODXSC" count="1" label="Cross-sectional"></FilterOption></Filter><Filter label="Trial Source" name="trialSources" total="2"><FilterOption id="CTGOVOTHERS" count="23" label="ClinicalTrials.gov and others"></FilterOption><FilterOption id="CTGOV" count="18" label="ClinicalTrials.gov only"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Primary" name="trialActionsSecondaryInterventionsPrimary" total="41"><FilterOption id="1545" count="21" label="Anticancer"></FilterOption><FilterOption id="767" count="15" label="Cell cycle inhibitor"></FilterOption><FilterOption id="55685" count="12" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="62255" count="12" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="2575" count="9" label="Microtubule inhibitor"></FilterOption><FilterOption id="2953" count="8" label="Anti-inflammatory"></FilterOption><FilterOption id="140" count="8" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="1569" count="7" label="Anticancer antimetabolite"></FilterOption><FilterOption id="61" count="6" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="2660" count="6" label="Vasoprotectant"></FilterOption><FilterOption id="1589" count="5" label="Apoptosis stimulator"></FilterOption><FilterOption id="2576" count="5" label="Microtubule stabilizer"></FilterOption><FilterOption id="50" count="4" label="Anticancer alkylating agent"></FilterOption><FilterOption id="750" count="3" label="DNA intercalator"></FilterOption><FilterOption id="449" count="2" label="Antiarrhythmic agent"></FilterOption><FilterOption id="71" count="2" label="Antihypercholesterolemic agent"></FilterOption><FilterOption id="2657" count="2" label="Antihypertensive"></FilterOption><FilterOption id="2516" count="2" label="LDL cholesterol modulator"></FilterOption><FilterOption id="7225" count="2" label="Psychostimulant"></FilterOption><FilterOption id="7293" count="2" label="Synergist"></FilterOption><FilterOption id="3" count="1" label="5-HT uptake inhibitor"></FilterOption><FilterOption id="62254" count="1" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="2941" count="1" label="Antidepressant"></FilterOption><FilterOption id="74" count="1" label="Antioxidant agent"></FilterOption><FilterOption id="991" count="1" label="Antiviral"></FilterOption><FilterOption id="2942" count="1" label="Anxiolytic"></FilterOption><FilterOption id="966" count="1" label="Cardiac agent"></FilterOption><FilterOption id="66" count="1" label="Class II antiarrhythmic agent"></FilterOption><FilterOption id="659" count="1" label="Coagulation inhibitor"></FilterOption><FilterOption id="805" count="1" label="Folate modulator"></FilterOption><FilterOption id="47084" count="1" label="Ganglioside GD2 inhibitor"></FilterOption><FilterOption id="3272" count="1" label="Growth hormone release inhibitor"></FilterOption><FilterOption id="610" count="1" label="Hematopoietic stimulator"></FilterOption><FilterOption id="38211" count="1" label="Human insulin fast acting product"></FilterOption><FilterOption id="38212" count="1" label="Human insulin intermediate acting product"></FilterOption><FilterOption id="399" count="1" label="Hypoglycemic agent"></FilterOption><FilterOption id="1129" count="1" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="285" count="1" label="Norepinephrine uptake inhibitor"></FilterOption><FilterOption id="312" count="1" label="Platelet aggregation inhibitor"></FilterOption><FilterOption id="1470" count="1" label="Respiratory system agent"></FilterOption><FilterOption id="388" count="1" label="Vasodilator"></FilterOption></Filter><Filter label="Trial Endpoint Achieved" name="trialEndpointsAchieved" total="3"><FilterOption id="UNSPECIFIED" count="11" label="Unspecified"></FilterOption><FilterOption id="YES" count="8" label="Yes"></FilterOption><FilterOption id="NO" count="3" label="No"></FilterOption></Filter><Filter label="Endpoint Index Secondary" name="trialEndpointIndexSecondary" total="100"><FilterOption id="8481" count="9" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8712" count="8" label="Breast tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8639" count="8" label="Lung tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8524" count="5" label="Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"></FilterOption><FilterOption id="8642" count="4" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicities (Upper and Lower)"></FilterOption><FilterOption id="8645" count="4" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of hematological toxicities"></FilterOption><FilterOption id="8563" count="4" label="Lung tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="8714" count="3" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="8719" count="3" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)"></FilterOption><FilterOption id="8996" count="3" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="2623" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="2622" count="3" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2774" count="3" label="Coronary artery disease - Assessment of hospitalization"></FilterOption><FilterOption id="22595" count="3" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="8505" count="3" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8489" count="3" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8516" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8522" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response"></FilterOption><FilterOption id="8641" count="3" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events"></FilterOption><FilterOption id="8649" count="3" label="Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations"></FilterOption><FilterOption id="24178" count="3" label="Stroke - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="2859" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Non fatal myocardial infarction"></FilterOption><FilterOption id="2864" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2981" count="2" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2957" count="2" label="Acute coronary syndrome - Assessment of Reperfusion/Revascularization"></FilterOption><FilterOption id="2871" count="2" label="Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Non-fatal Stroke"></FilterOption><FilterOption id="2952" count="2" label="Acute coronary syndrome - Assessment of hospitalization"></FilterOption><FilterOption id="9980" count="2" label="Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)"></FilterOption><FilterOption id="9954" count="2" label="Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)"></FilterOption><FilterOption id="37159" count="2" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8754" count="2" label="Breast tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8815" count="2" label="Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu"></FilterOption><FilterOption id="8713" count="2" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8722" count="2" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2503" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2515" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"></FilterOption><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22597" count="2" label="End stage renal disease - Assessment of hospitalization - Assessment of Hospitalization Rates"></FilterOption><FilterOption id="23937" count="2" label="Hypercholesterolemia - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23944" count="2" label="Hypercholesterolemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="23072" count="2" label="Lipid metabolism disorder - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23079" count="2" label="Lipid metabolism disorder - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8549" count="2" label="Lung tumor - Assessment of Clinical Symptoms - Symptom assessment by lung cancer symptom scale (LCSS)"></FilterOption><FilterOption id="8504" count="2" label="Lung tumor - Assessment of Objective Response"></FilterOption><FilterOption id="8508" count="2" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="8483" count="2" label="Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 1 year"></FilterOption><FilterOption id="8663" count="2" label="Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters"></FilterOption><FilterOption id="8514" count="2" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8513" count="2" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8640" count="2" label="Lung tumor - Assessment of Safety and Tolerability - Adverse events as graded by CTCAE/CTC"></FilterOption><FilterOption id="8643" count="2" label="Lung tumor - Assessment of Safety and Tolerability - Assessment of pulmonary toxicities"></FilterOption><FilterOption id="24187" count="2" label="Stroke - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="24177" count="2" label="Stroke - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="2980" count="1" label="Acute coronary syndrome - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="17294" count="1" label="Anemia - Hematological Assessments - Assessment of hemoglobin response"></FilterOption><FilterOption id="9502" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events"></FilterOption><FilterOption id="9510" count="1" label="Atrial fibrillation - Assessment of Hemorrhagic Complications - Assessment of major bleeding events"></FilterOption><FilterOption id="9438" count="1" label="Atrial fibrillation - Assessment of Mortality/Death Rates - Assessment of all cause death"></FilterOption><FilterOption id="9519" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"></FilterOption><FilterOption id="9444" count="1" label="Atrial fibrillation - Assessments of Composite Endpoints"></FilterOption><FilterOption id="9941" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)"></FilterOption><FilterOption id="9942" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Quick Inventory Depressive Symptoms (QIDS)"></FilterOption><FilterOption id="8983" count="1" label="Breast tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="8745" count="1" label="Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)"></FilterOption><FilterOption id="8744" count="1" label="Breast tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8743" count="1" label="Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of local relapses"></FilterOption><FilterOption id="8740" count="1" label="Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of time to recurrence"></FilterOption><FilterOption id="8971" count="1" label="Breast tumor - Assessment of Hormone Levels"></FilterOption><FilterOption id="8829" count="1" label="Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation"></FilterOption><FilterOption id="8749" count="1" label="Breast tumor - Assessment of Metastasis"></FilterOption><FilterOption id="8817" count="1" label="Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of cMYC expression"></FilterOption><FilterOption id="8721" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8720" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="8725" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8738" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response"></FilterOption><FilterOption id="8727" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of radiographic response"></FilterOption><FilterOption id="8737" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of time to tumor response"></FilterOption><FilterOption id="9001" count="1" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of cardiac toxicity"></FilterOption><FilterOption id="9012" count="1" label="Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity"></FilterOption><FilterOption id="45149" count="1" label="Breast tumor - Assessment of Survival"></FilterOption><FilterOption id="37161" count="1" label="Breast tumor - Assessment of Tumor Related Parameters"></FilterOption><FilterOption id="8827" count="1" label="Breast tumor - Assessment of Tumor Suppressor Genes/Proteins - Assessment of Phosphatase and tensin homolog (PTEN) status"></FilterOption><FilterOption id="8998" count="1" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="45566" count="1" label="Breast tumor - Clinical Assessments"></FilterOption><FilterOption id="9307" count="1" label="Breast tumor - Hormone Receptor Status - Estrogen receptor status"></FilterOption><FilterOption id="9308" count="1" label="Breast tumor - Hormone Receptor Status - Progesterone receptor status"></FilterOption><FilterOption id="8805" count="1" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT - Breast Cancer (FACT-B)"></FilterOption><FilterOption id="8759" count="1" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9103" count="1" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of Rate of Breast Conserving Surgery"></FilterOption><FilterOption id="9334" count="1" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of lymph nodes"></FilterOption><FilterOption id="9043" count="1" label="Breast tumor - Protocol Specified Other Endpoints"></FilterOption><FilterOption id="2492" count="1" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="2610" count="1" label="Coronary artery disease - Assessment of Clinical Symptoms - Assessment of arrhythmia"></FilterOption><FilterOption id="2616" count="1" label="Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)"></FilterOption><FilterOption id="2700" count="1" label="Coronary artery disease - Assessment of Reperfusion/Revascularization - Need for a revascularization procedure"></FilterOption><FilterOption id="2689" count="1" label="Coronary artery disease - Assessment of Reperfusion/Revascularization"></FilterOption><FilterOption id="2803" count="1" label="Coronary artery disease - Protocol Specified Other Endpoints"></FilterOption><FilterOption id="10732" count="1" label="Depression - Assessment of Clinical Symptoms - Assessment of anxiety symptoms"></FilterOption></Filter><Filter label="Biomarker" name="trialBiomarkerNames" total="75"><FilterOption id="3" count="9" label="HER2"></FilterOption><FilterOption id="5" count="6" label="Estrogen receptor"></FilterOption><FilterOption id="1945" count="4" label="Left ventricular ejection fraction"></FilterOption><FilterOption id="1211" count="3" label="Alanine transaminase"></FilterOption><FilterOption id="8" count="3" label="Epidermal growth factor receptor"></FilterOption><FilterOption id="1236" count="3" label="Hemoglobin"></FilterOption><FilterOption id="152" count="3" label="Low-density lipoprotein cholesterol"></FilterOption><FilterOption id="6" count="3" label="Progesterone receptor"></FilterOption><FilterOption id="12058" count="3" label="Total body mass"></FilterOption><FilterOption id="7" count="2" label="Antigen KI-67"></FilterOption><FilterOption id="214" count="2" label="Apolipoprotein A-I"></FilterOption><FilterOption id="215" count="2" label="Apolipoprotein B-100"></FilterOption><FilterOption id="150" count="2" label="Apolipoprotein(a)"></FilterOption><FilterOption id="113" count="2" label="Body Mass Index"></FilterOption><FilterOption id="3374" count="2" label="Bone mineral density"></FilterOption><FilterOption id="22" count="2" label="Breast cancer type 1 susceptibility protein"></FilterOption><FilterOption id="46" count="2" label="C-reactive protein"></FilterOption><FilterOption id="8024" count="2" label="Creatine kinase"></FilterOption><FilterOption id="332" count="2" label="Diastolic blood pressure"></FilterOption><FilterOption id="153" count="2" label="High-density lipoprotein cholesterol"></FilterOption><FilterOption id="14767" count="2" label="Lipids"></FilterOption><FilterOption id="1925" count="2" label="Neutrophils"></FilterOption><FilterOption id="2053" count="2" label="Non-high density lipoprotein cholesterol"></FilterOption><FilterOption id="1196" count="2" label="Remnant-like particle cholesterol"></FilterOption><FilterOption id="330" count="2" label="Systolic blood pressure"></FilterOption><FilterOption id="133" count="2" label="Total cholesterol"></FilterOption><FilterOption id="217" count="2" label="Triglycerides"></FilterOption><FilterOption id="1289" count="2" label="Tumor mass"></FilterOption><FilterOption id="11563" count="2" label="Very low density lipoprotein cholesterol"></FilterOption><FilterOption id="16446" count="1" label="Alkaline phosphatase, bone specific"></FilterOption><FilterOption id="2527" count="1" label="Aspartate aminotransferase"></FilterOption><FilterOption id="6997" count="1" label="Bcl-2-like protein 11"></FilterOption><FilterOption id="2054" count="1" label="Blood platelets"></FilterOption><FilterOption id="17697" count="1" label="Body height"></FilterOption><FilterOption id="41" count="1" label="Breast cancer type 2 susceptibility protein"></FilterOption><FilterOption id="30391" count="1" label="C-terminal telopeptide of collagen type I"></FilterOption><FilterOption id="9" count="1" label="Cellular tumor antigen p53"></FilterOption><FilterOption id="57" count="1" label="Chromogranin-A"></FilterOption><FilterOption id="483" count="1" label="Collagen type I trimeric cross-linked peptide"></FilterOption><FilterOption id="213" count="1" label="Creatinine"></FilterOption><FilterOption id="1774" count="1" label="Deoxypyridinoline"></FilterOption><FilterOption id="10306" count="1" label="Ejection fraction"></FilterOption><FilterOption id="1634" count="1" label="Endometrium"></FilterOption><FilterOption id="6268" count="1" label="ERK1/2"></FilterOption><FilterOption id="2884" count="1" label="FKBP12-rapamycin complex-associated protein"></FilterOption><FilterOption id="8458" count="1" label="gamma-Glutamyltransferase"></FilterOption><FilterOption id="1735" count="1" label="Glucose"></FilterOption><FilterOption id="193" count="1" label="Growth differentiation factor 15"></FilterOption><FilterOption id="924" count="1" label="GTPase HRas"></FilterOption><FilterOption id="1904" count="1" label="Heart rate"></FilterOption><FilterOption id="1221" count="1" label="Hematocrit"></FilterOption><FilterOption id="289" count="1" label="Hemoglobin A, glycosylated"></FilterOption><FilterOption id="1563" count="1" label="HLA class II histocompatibility antigen, DRB1 beta chain"></FilterOption><FilterOption id="1550" count="1" label="Hydroxyindoleacetic Acid"></FilterOption><FilterOption id="9755" count="1" label="Left atrium"></FilterOption><FilterOption id="9580" count="1" label="Left ventricle"></FilterOption><FilterOption id="125" count="1" label="Leukocyte count"></FilterOption><FilterOption id="48953" count="1" label="Lumbar spine bone mineral density"></FilterOption><FilterOption id="3277" count="1" label="Mitogen Activated Protein Kinases"></FilterOption><FilterOption id="14" count="1" label="Myc proto-oncogene protein"></FilterOption><FilterOption id="106" count="1" label="N-terminal Pro Brain Natriuretic Peptide"></FilterOption><FilterOption id="1685" count="1" label="Nibrin"></FilterOption><FilterOption id="743" count="1" label="Osteocalcin"></FilterOption><FilterOption id="11792" count="1" label="Ovary"></FilterOption><FilterOption id="10" count="1" label="Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN"></FilterOption><FilterOption id="3388" count="1" label="Procollagen type I carboxy terminal peptide"></FilterOption><FilterOption id="40655" count="1" label="Ras GTPases"></FilterOption><FilterOption id="3583" count="1" label="SH3 and PX domain-containing protein 2A"></FilterOption><FilterOption id="95" count="1" label="Troponin T, cardiac muscle"></FilterOption><FilterOption id="2358" count="1" label="Urea nitrogen"></FilterOption><FilterOption id="288" count="1" label="Uric acid"></FilterOption><FilterOption id="12516" count="1" label="Urinary protein"></FilterOption><FilterOption id="12008" count="1" label="Uterus"></FilterOption><FilterOption id="11359" count="1" label="Vascular endothelial growth factors"></FilterOption><FilterOption id="419" count="1" label="Waist to Hip Ratio"></FilterOption></Filter><Filter label="Trial Terms Endpoint" name="trialTermsEndpoint" total="4"><FilterOption id="SIEEFC" count="32" label="Efficacy"></FilterOption><FilterOption id="SIESFT" count="32" label="Safety"></FilterOption><FilterOption id="SIEPCK" count="7" label="Pharmacokinetics"></FilterOption><FilterOption id="SIEPCD" count="6" label="Pharmacodynamics"></FilterOption></Filter><Filter label="Trial Interventions Primary In Regimen Name Display" name="trialInterventionsPrimaryInRegimenNameDisplay" total="21"><FilterOption id="2953" count="9" label="docetaxel"></FilterOption><FilterOption id="3803" count="5" label="paclitaxel"></FilterOption><FilterOption id="8047" count="4" label="bevacizumab"></FilterOption><FilterOption id="3199" count="4" label="gemcitabine"></FilterOption><FilterOption id="44383" count="3" label="carboplatin"></FilterOption><FilterOption id="6386" count="3" label="trastuzumab"></FilterOption><FilterOption id="12205" count="2" label="capecitabine"></FilterOption><FilterOption id="13022" count="2" label="epirubicin"></FilterOption><FilterOption id="11961" count="2" label="erlotinib"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="72524" count="1" label="dinutuximab"></FilterOption><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"></FilterOption><FilterOption id="3313" count="1" label="fulvestrant"></FilterOption><FilterOption id="10411" count="1" label="insulin aspart"></FilterOption><FilterOption id="17426" count="1" label="insulin detemir"></FilterOption><FilterOption id="2871" count="1" label="irinotecan"></FilterOption><FilterOption id="33591" count="1" label="lapatinib"></FilterOption><FilterOption id="3792" count="1" label="oxaliplatin"></FilterOption><FilterOption id="29016" count="1" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="28532" count="1" label="pertuzumab"></FilterOption><FilterOption id="6408" count="1" label="vinorelbine"></FilterOption></Filter><Filter label="Trial Document Source" name="trialDocumentSource" total="5"><FilterOption id="SERIAL" count="18" label="Serial Publications"></FilterOption><FilterOption id="OTHER" count="17" label="Other Publications"></FilterOption><FilterOption id="PR" count="10" label="Press Releases"></FilterOption><FilterOption id="CONFERENCE" count="2" label="Conference Reports"></FilterOption><FilterOption id="CORPORATE" count="1" label="Corporate Publications"></FilterOption></Filter><Filter label="Trial Interventions Primary Alone Name Display" name="trialInterventionsPrimaryAloneNameDisplay" total="21"><FilterOption id="11961" count="3" label="erlotinib"></FilterOption><FilterOption id="48357" count="2" label="armodafinil"></FilterOption><FilterOption id="8047" count="2" label="bevacizumab"></FilterOption><FilterOption id="64571" count="2" label="bococizumab"></FilterOption><FilterOption id="72538" count="1" label="abemaciclib"></FilterOption><FilterOption id="44280" count="1" label="atenolol"></FilterOption><FilterOption id="44372" count="1" label="bisoprolol fumarate"></FilterOption><FilterOption id="8955" count="1" label="carvedilol"></FilterOption><FilterOption id="51255" count="1" label="edoxaban"></FilterOption><FilterOption id="8121" count="1" label="epoetin beta, Roche"></FilterOption><FilterOption id="3081" count="1" label="exemestane"></FilterOption><FilterOption id="17558" count="1" label="fluoxetine hydrochloride"></FilterOption><FilterOption id="9313" count="1" label="lanreotide"></FilterOption><FilterOption id="33591" count="1" label="lapatinib"></FilterOption><FilterOption id="3686" count="1" label="nebivolol"></FilterOption><FilterOption id="98707" count="1" label="nemorexant"></FilterOption><FilterOption id="3536" count="1" label="pemetrexed disodium"></FilterOption><FilterOption id="17113" count="1" label="tipifarnib"></FilterOption><FilterOption id="62282" count="1" label="trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme"></FilterOption><FilterOption id="6386" count="1" label="trastuzumab"></FilterOption><FilterOption id="4648" count="1" label="venlafaxine hydrochloride"></FilterOption></Filter><Filter label="Trial Interventions Control In Regimen Name Display" name="trialInterventionsControlInRegimenNameDisplay" total="6"><FilterOption id="44383" count="2" label="carboplatin"></FilterOption><FilterOption id="2953" count="2" label="docetaxel"></FilterOption><FilterOption id="3199" count="1" label="gemcitabine"></FilterOption><FilterOption id="10411" count="1" label="insulin aspart"></FilterOption><FilterOption id="3803" count="1" label="paclitaxel"></FilterOption><FilterOption id="6386" count="1" label="trastuzumab"></FilterOption></Filter><Filter label="Trial Category" name="trialCategory" total="6"><FilterOption id="4" count="31" label="Small molecule"></FilterOption><FilterOption id="3" count="18" label="Biological"></FilterOption><FilterOption id="17" count="1" label="Biomarker identification"></FilterOption><FilterOption id="11" count="1" label="Dietary supplement"></FilterOption><FilterOption id="9" count="1" label="Medical procedure"></FilterOption><FilterOption id="15" count="1" label="Radiation therapy"></FilterOption></Filter><Filter label="Trial Outcome Available" name="trialOutcomesAvailable" total="2"><FilterOption id="YES" count="22" label="Yes"></FilterOption><FilterOption id="NO" count="20" label="No"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Primary" name="trialActionsPrimaryInterventionsPrimary" total="35"><FilterOption id="740" count="7" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="12521" count="6" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="3754" count="5" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="3756" count="5" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="372" count="3" label="Thymidylate synthase inhibitor"></FilterOption><FilterOption id="142" count="3" label="Topoisomerase II inhibitor"></FilterOption><FilterOption id="31" count="2" label="Alpha 1 adrenoceptor agonist"></FilterOption><FilterOption id="76" count="2" label="Aromatase inhibitor"></FilterOption><FilterOption id="82444" count="2" label="DNA helicase inhibitor"></FilterOption><FilterOption id="13181" count="2" label="Dopamine transporter inhibitor"></FilterOption><FilterOption id="48843" count="2" label="Proprotein convertase PC9 inhibitor"></FilterOption><FilterOption id="30" count="1" label="Alpha adrenoceptor antagonist"></FilterOption><FilterOption id="39" count="1" label="Beta 1 adrenoceptor antagonist"></FilterOption><FilterOption id="42" count="1" label="Beta 3 adrenoceptor agonist"></FilterOption><FilterOption id="38" count="1" label="Beta adrenoceptor antagonist"></FilterOption><FilterOption id="4314" count="1" label="Cyclin-dependent kinase-4 inhibitor"></FilterOption><FilterOption id="4318" count="1" label="Cyclin-dependent kinase-6 inhibitor"></FilterOption><FilterOption id="135" count="1" label="DHFR inhibitor"></FilterOption><FilterOption id="138" count="1" label="DNA polymerase inhibitor"></FilterOption><FilterOption id="12162" count="1" label="Erythropoietin ligand"></FilterOption><FilterOption id="286" count="1" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="120" count="1" label="Factor Xa antagonist"></FilterOption><FilterOption id="181" count="1" label="GAR transformylase inhibitor"></FilterOption><FilterOption id="8590" count="1" label="Hyaluronidase stimulator"></FilterOption><FilterOption id="23014" count="1" label="Insulin ligand"></FilterOption><FilterOption id="400" count="1" label="Insulin receptor agonist"></FilterOption><FilterOption id="3252" count="1" label="Insulin-like growth factor 1 receptor antagonist"></FilterOption><FilterOption id="6888" count="1" label="Orexin 1 receptor antagonist"></FilterOption><FilterOption id="6891" count="1" label="Orexin 2 receptor antagonist"></FilterOption><FilterOption id="4528" count="1" label="PIM-1 protein kinase inhibitor"></FilterOption><FilterOption id="1875" count="1" label="Protein farnesyltransferase inhibitor"></FilterOption><FilterOption id="10451" count="1" label="Ras GTPase inhibitor"></FilterOption><FilterOption id="1120" count="1" label="Somatostatin receptor agonist"></FilterOption><FilterOption id="141" count="1" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="374" count="1" label="Transferase inhibitor"></FilterOption></Filter><Filter label="Trial Company Collaborator" name="trialCompaniesCollaborator" total="20"><FilterOption id="19446" count="3" label="Roche Holding AG"></FilterOption><FilterOption id="20519" count="2" label="National Cancer Institute"></FilterOption><FilterOption id="20348" count="2" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="14109" count="1" label="Amgen Inc"></FilterOption><FilterOption id="14190" count="1" label="AstraZeneca plc"></FilterOption><FilterOption id="1096161" count="1" label="Australia &amp; New Zealand Breast Cancer Trials Group"></FilterOption><FilterOption id="1042255" count="1" label="Breast International Group"></FilterOption><FilterOption id="15065" count="1" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1120666" count="1" label="Canadian Cancer Trials Group"></FilterOption><FilterOption id="15358" count="1" label="Cephalon Inc"></FilterOption><FilterOption id="23119" count="1" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1042350" count="1" label="Federation Francophone de Cancerologie Digestive"></FilterOption><FilterOption id="1080644" count="1" label="Grupo de Tratamiento de los Tumores Digestivos"></FilterOption><FilterOption id="1042243" count="1" label="International Breast Cancer Study Group"></FilterOption><FilterOption id="1042355" count="1" label="International Collaborative Cancer Group"></FilterOption><FilterOption id="1037951" count="1" label="North Central Cancer Treatment Group"></FilterOption><FilterOption id="18767" count="1" label="Pfizer Inc"></FilterOption><FilterOption id="1182419" count="1" label="Pierre Fabre Iberica, S.A."></FilterOption><FilterOption id="1009547" count="1" label="Sanofi SA"></FilterOption><FilterOption id="1050186" count="1" label="The TIMI Study Group"></FilterOption></Filter><Filter label="Trial Actions Secondary Interventions Control" name="trialActionsSecondaryInterventionsControl" total="18"><FilterOption id="1545" count="6" label="Anticancer"></FilterOption><FilterOption id="50" count="2" label="Anticancer alkylating agent"></FilterOption><FilterOption id="55685" count="2" label="Anticancer monoclonal antibody"></FilterOption><FilterOption id="62255" count="2" label="Anticancer protein kinase inhibitor"></FilterOption><FilterOption id="767" count="2" label="Cell cycle inhibitor"></FilterOption><FilterOption id="140" count="2" label="DNA synthesis inhibitor"></FilterOption><FilterOption id="2575" count="2" label="Microtubule inhibitor"></FilterOption><FilterOption id="61" count="1" label="Angiogenesis inhibitor"></FilterOption><FilterOption id="2953" count="1" label="Anti-inflammatory"></FilterOption><FilterOption id="1569" count="1" label="Anticancer antimetabolite"></FilterOption><FilterOption id="62254" count="1" label="Anticancer hormone antagonist"></FilterOption><FilterOption id="1589" count="1" label="Apoptosis stimulator"></FilterOption><FilterOption id="659" count="1" label="Coagulation inhibitor"></FilterOption><FilterOption id="38211" count="1" label="Human insulin fast acting product"></FilterOption><FilterOption id="399" count="1" label="Hypoglycemic agent"></FilterOption><FilterOption id="2576" count="1" label="Microtubule stabilizer"></FilterOption><FilterOption id="1129" count="1" label="Non-steroid hormone receptor antagonist"></FilterOption><FilterOption id="2660" count="1" label="Vasoprotectant"></FilterOption></Filter><Filter label="Biomarker Type" name="trialBiomarkerTypes" total="7"><FilterOption id="38" count="21" label="Genomic"></FilterOption><FilterOption id="37" count="21" label="Proteomic"></FilterOption><FilterOption id="32" count="9" label="Biochemical"></FilterOption><FilterOption id="31" count="7" label="Physiological"></FilterOption><FilterOption id="39" count="4" label="Anthropomorphic"></FilterOption><FilterOption id="40" count="4" label="Structural (imaging)"></FilterOption><FilterOption id="75" count="2" label="Cellular"></FilterOption></Filter><Filter label="Biomarker Role" name="trialBiomarkerRoles" total="3"><FilterOption id="1571666123" count="16" label="Disease marker"></FilterOption><FilterOption id="695863716" count="15" label="Therapeutic effect marker"></FilterOption><FilterOption id="730490367" count="10" label="Toxic effect marker"></FilterOption></Filter><Filter label="Interventions" name="trialInterventions" total="38"><FilterOption id="2953" count="9" label="docetaxel"></FilterOption><FilterOption id="8047" count="6" label="bevacizumab"></FilterOption><FilterOption id="11961" count="5" label="erlotinib"></FilterOption><FilterOption id="3803" count="5" label="paclitaxel"></FilterOption><FilterOption id="3199" count="4" label="gemcitabine"></FilterOption><FilterOption id="6386" count="4" label="trastuzumab"></FilterOption><FilterOption id="44383" count="3" label="carboplatin"></FilterOption><FilterOption id="48357" count="2" label="armodafinil"></FilterOption><FilterOption id="64571" count="2" label="bococizumab"></FilterOption><FilterOption id="12205" count="2" label="capecitabine"></FilterOption><FilterOption id="13022" count="2" label="epirubicin"></FilterOption><FilterOption id="72538" count="1" label="abemaciclib"></FilterOption><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="44280" count="1" label="atenolol"></FilterOption><FilterOption id="44372" count="1" label="bisoprolol fumarate"></FilterOption><FilterOption id="8955" count="1" label="carvedilol"></FilterOption><FilterOption id="72524" count="1" label="dinutuximab"></FilterOption><FilterOption id="4563" count="1" label="doxorubicin (liposome formulation), Cephalon"></FilterOption><FilterOption id="51255" count="1" label="edoxaban"></FilterOption><FilterOption id="8121" count="1" label="epoetin beta, Roche"></FilterOption><FilterOption id="3081" count="1" label="exemestane"></FilterOption><FilterOption id="17558" count="1" label="fluoxetine hydrochloride"></FilterOption><FilterOption id="3313" count="1" label="fulvestrant"></FilterOption><FilterOption id="10411" count="1" label="insulin aspart"></FilterOption><FilterOption id="17426" count="1" label="insulin detemir"></FilterOption><FilterOption id="2871" count="1" label="irinotecan"></FilterOption><FilterOption id="9313" count="1" label="lanreotide"></FilterOption><FilterOption id="33591" count="1" label="lapatinib"></FilterOption><FilterOption id="3686" count="1" label="nebivolol"></FilterOption><FilterOption id="98707" count="1" label="nemorexant"></FilterOption><FilterOption id="3792" count="1" label="oxaliplatin"></FilterOption><FilterOption id="29016" count="1" label="paclitaxel (albumin-bound nanoparticle, intravenous), Celgene"></FilterOption><FilterOption id="3536" count="1" label="pemetrexed disodium"></FilterOption><FilterOption id="28532" count="1" label="pertuzumab"></FilterOption><FilterOption id="17113" count="1" label="tipifarnib"></FilterOption><FilterOption id="62282" count="1" label="trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme"></FilterOption><FilterOption id="4648" count="1" label="venlafaxine hydrochloride"></FilterOption><FilterOption id="6408" count="1" label="vinorelbine"></FilterOption></Filter><Filter label="Endpoint Index Primary" name="trialEndpointIndexPrimary" total="100"><FilterOption id="8489" count="5" label="Lung tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8714" count="4" label="Breast tumor - Assessment of Disease Free Survival (DFS)"></FilterOption><FilterOption id="2774" count="3" label="Coronary artery disease - Assessment of hospitalization"></FilterOption><FilterOption id="8514" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response"></FilterOption><FilterOption id="8513" count="3" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)"></FilterOption><FilterOption id="2859" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Non fatal myocardial infarction"></FilterOption><FilterOption id="2864" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2853" count="2" label="Acute coronary syndrome - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="2981" count="2" label="Acute coronary syndrome - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2871" count="2" label="Acute coronary syndrome - Assessment of Thrombotic/Thromboembolic Events - Non-fatal Stroke"></FilterOption><FilterOption id="8998" count="2" label="Breast tumor - Assessment of adverse events"></FilterOption><FilterOption id="2494" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Fatal MI/Non-fatal MI"></FilterOption><FilterOption id="2503" count="2" label="Coronary artery disease - Assessment of Cardiovascular Events - Unstable angina"></FilterOption><FilterOption id="2622" count="2" label="Coronary artery disease - Assessment of Mortality/Death Rates - Cardiovascular mortality"></FilterOption><FilterOption id="2609" count="2" label="Coronary artery disease - Assessment of Other Cardiovascular Events"></FilterOption><FilterOption id="2515" count="2" label="Coronary artery disease - Assessment of Thrombotic/Thromboembolic Events - Fatal /Non-fatal stroke"></FilterOption><FilterOption id="22539" count="2" label="End stage renal disease - Assessment of Cardiac Function"></FilterOption><FilterOption id="22596" count="2" label="End stage renal disease - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="22595" count="2" label="End stage renal disease - Assessment of adverse events"></FilterOption><FilterOption id="22597" count="2" label="End stage renal disease - Assessment of hospitalization - Assessment of Hospitalization Rates"></FilterOption><FilterOption id="23937" count="2" label="Hypercholesterolemia - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23944" count="2" label="Hypercholesterolemia - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="23072" count="2" label="Lipid metabolism disorder - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="23079" count="2" label="Lipid metabolism disorder - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8523" count="2" label="Lung tumor - Assessment of Disease Progression"></FilterOption><FilterOption id="8555" count="2" label="Lung tumor - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="8508" count="2" label="Lung tumor - Assessment of Overall Response"></FilterOption><FilterOption id="23562" count="2" label="Menopause - Assessment of Therapy Related Outcomes - Assessment of response to cancer therapy"></FilterOption><FilterOption id="24187" count="2" label="Stroke - Assessment of Cardiovascular Events - Assessment of myocardial infarction"></FilterOption><FilterOption id="24185" count="2" label="Stroke - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="24177" count="2" label="Stroke - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="24193" count="2" label="Stroke - Assessment of Stroke - Assessment of fatal/nonfatal stroke"></FilterOption><FilterOption id="2957" count="1" label="Acute coronary syndrome - Assessment of Reperfusion/Revascularization"></FilterOption><FilterOption id="2952" count="1" label="Acute coronary syndrome - Assessment of hospitalization"></FilterOption><FilterOption id="17356" count="1" label="Anemia - Assessment of adverse events"></FilterOption><FilterOption id="9502" count="1" label="Atrial fibrillation - Assessment of Cerebrovascular Events"></FilterOption><FilterOption id="9519" count="1" label="Atrial fibrillation - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"></FilterOption><FilterOption id="9444" count="1" label="Atrial fibrillation - Assessments of Composite Endpoints"></FilterOption><FilterOption id="9948" count="1" label="Bipolar disorder - Assessment of Anxiety by Protocol Specified Scales - Assessment by Hamilton Anxiety Rating Scale (HAM-A)"></FilterOption><FilterOption id="10013" count="1" label="Bipolar disorder - Assessment of Cardiac Function"></FilterOption><FilterOption id="9941" count="1" label="Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)"></FilterOption><FilterOption id="10016" count="1" label="Bipolar disorder - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="9932" count="1" label="Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)"></FilterOption><FilterOption id="10005" count="1" label="Bipolar disorder - Assessment of Physical Examination"></FilterOption><FilterOption id="10025" count="1" label="Bipolar disorder - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="9989" count="1" label="Bipolar disorder - Assessment of Sleep"></FilterOption><FilterOption id="10007" count="1" label="Bipolar disorder - Assessment of Vital Signs"></FilterOption><FilterOption id="10026" count="1" label="Bipolar disorder - Assessment of adverse events"></FilterOption><FilterOption id="9946" count="1" label="Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)"></FilterOption><FilterOption id="9042" count="1" label="Breast tumor - Anthropometric Assessments"></FilterOption><FilterOption id="8983" count="1" label="Breast tumor - Assessment of Biopsy/Cytology/Histology"></FilterOption><FilterOption id="8743" count="1" label="Breast tumor - Assessment of Disease Relapse/Recurrence - Assessment of local relapses"></FilterOption><FilterOption id="37159" count="1" label="Breast tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8829" count="1" label="Breast tumor - Assessment of Markers of Tumor Growth and Progression - Assessment of markers of proliferation"></FilterOption><FilterOption id="8749" count="1" label="Breast tumor - Assessment of Metastasis"></FilterOption><FilterOption id="9309" count="1" label="Breast tumor - Assessment of Morbidity Rates"></FilterOption><FilterOption id="45699" count="1" label="Breast tumor - Assessment of Neuropsychological Function"></FilterOption><FilterOption id="8815" count="1" label="Breast tumor - Assessment of Oncogenes/Oncoproteins - Assessment of Human epidermal growth factor receptor-2/ErbB2/neu"></FilterOption><FilterOption id="8792" count="1" label="Breast tumor - Assessment of Performance Status - WHO/ECOG performance status"></FilterOption><FilterOption id="8713" count="1" label="Breast tumor - Assessment of Progression Free Survival (PFS)"></FilterOption><FilterOption id="8725" count="1" label="Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8996" count="1" label="Breast tumor - Assessment of Safety and Tolerability"></FilterOption><FilterOption id="8750" count="1" label="Breast tumor - Assessment of Treatment Withdrawal"></FilterOption><FilterOption id="37161" count="1" label="Breast tumor - Assessment of Tumor Related Parameters"></FilterOption><FilterOption id="8828" count="1" label="Breast tumor - Assessment of Tumor Suppressor Genes/Proteins - Assessment of Breast Cancer Gene (BRCA)"></FilterOption><FilterOption id="9306" count="1" label="Breast tumor - Hormone Receptor Status"></FilterOption><FilterOption id="8759" count="1" label="Breast tumor - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="9103" count="1" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of Rate of Breast Conserving Surgery"></FilterOption><FilterOption id="9334" count="1" label="Breast tumor - Protocol Specified Other Endpoints - Assessment of lymph nodes"></FilterOption><FilterOption id="45141" count="1" label="Cancer supportive care - Assessment of Clinical Symptoms"></FilterOption><FilterOption id="19264" count="1" label="Cancer supportive care - Assessment of Disease Progression"></FilterOption><FilterOption id="19399" count="1" label="Cancer supportive care - Assessment of Mortality/Death Rates"></FilterOption><FilterOption id="45181" count="1" label="Cancer supportive care - Clinical Assessments"></FilterOption><FilterOption id="19282" count="1" label="Cancer supportive care - Patient Reported Outcomes/Quality of Life Assessments"></FilterOption><FilterOption id="19411" count="1" label="Cancer supportive care - Protocol Specified Other Endpoints"></FilterOption><FilterOption id="2492" count="1" label="Coronary artery disease - Assessment of Cardiovascular Events - Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)"></FilterOption><FilterOption id="2623" count="1" label="Coronary artery disease - Assessment of Mortality/Death Rates - Assessment of all cause mortality"></FilterOption><FilterOption id="2616" count="1" label="Coronary artery disease - Assessment of Other Cardiovascular Events - Heart failure (New onset /Worsening)"></FilterOption><FilterOption id="2700" count="1" label="Coronary artery disease - Assessment of Reperfusion/Revascularization - Need for a revascularization procedure"></FilterOption><FilterOption id="2803" count="1" label="Coronary artery disease - Protocol Specified Other Endpoints"></FilterOption><FilterOption id="10742" count="1" label="Depression - Assessment of Depression Severity by Specific Criteria - Assessment by Montgomery-Asberg Depression Scale (MADRS)"></FilterOption><FilterOption id="10809" count="1" label="Depression - Assessment of Therapy Related Outcomes"></FilterOption><FilterOption id="35787" count="1" label="Depression - Health Economic Assessments - Health care resource utilization"></FilterOption><FilterOption id="22537" count="1" label="End stage renal disease - Glycemic Control Analysis - Assessment of glycosylated hemoglobin (HbA1c)"></FilterOption><FilterOption id="14851" count="1" label="Heart arrhythmia - Assessment of Cerebrovascular Events"></FilterOption><FilterOption id="14868" count="1" label="Heart arrhythmia - Assessment of Thrombotic/Thromboembolic Events - Assessment of systemic thromboembolism"></FilterOption><FilterOption id="14793" count="1" label="Heart arrhythmia - Assessments of Composite Endpoints"></FilterOption><FilterOption id="2" count="1" label="Hypertension - Assessment of Blood Pressure (BP) - BP control rate"></FilterOption><FilterOption id="23666" count="1" label="Insomnia - Assessment of Safety and Tolerability - Assessment of serious adverse events"></FilterOption><FilterOption id="23665" count="1" label="Insomnia - Assessment of adverse events"></FilterOption><FilterOption id="18111" count="1" label="Insulin dependent diabetes - Assessment of HbA1c Levels"></FilterOption><FilterOption id="8644" count="1" label="Lung tumor - Assessment of Cardiovascular Events"></FilterOption><FilterOption id="8549" count="1" label="Lung tumor - Assessment of Clinical Symptoms - Symptom assessment by lung cancer symptom scale (LCSS)"></FilterOption><FilterOption id="8524" count="1" label="Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)"></FilterOption><FilterOption id="8651" count="1" label="Lung tumor - Assessment of Laboratory/Diagnostic Measures"></FilterOption><FilterOption id="8505" count="1" label="Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)"></FilterOption><FilterOption id="8481" count="1" label="Lung tumor - Assessment of Overall Survival (OS)"></FilterOption><FilterOption id="8495" count="1" label="Lung tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 6 months"></FilterOption><FilterOption id="8516" count="1" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease"></FilterOption><FilterOption id="8519" count="1" label="Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)"></FilterOption></Filter><Filter label="Sponsors/Collaborators" name="trialCompanies" total="47"><FilterOption id="19446" count="14" label="Roche Holding AG"></FilterOption><FilterOption id="18767" count="4" label="Pfizer Inc"></FilterOption><FilterOption id="1042061" count="4" label="Spanish Breast Cancer Research Group"></FilterOption><FilterOption id="15358" count="3" label="Cephalon Inc"></FilterOption><FilterOption id="26178" count="3" label="F Hoffmann-La Roche AG"></FilterOption><FilterOption id="1041586" count="2" label="Arnau de Vilanova Hospital"></FilterOption><FilterOption id="14190" count="2" label="AstraZeneca plc"></FilterOption><FilterOption id="17810" count="2" label="Eli Lilly &amp; Co"></FilterOption><FilterOption id="20519" count="2" label="National Cancer Institute"></FilterOption><FilterOption id="1045513" count="2" label="Spanish Lung Cancer Group"></FilterOption><FilterOption id="20348" count="2" label="Teva Pharmaceutical Industries Ltd"></FilterOption><FilterOption id="14109" count="1" label="Amgen Inc"></FilterOption><FilterOption id="1064840" count="1" label="Asociacion para el Progreso de la Oncologia en Malaga"></FilterOption><FilterOption id="1096161" count="1" label="Australia &amp; New Zealand Breast Cancer Trials Group"></FilterOption><FilterOption id="1042255" count="1" label="Breast International Group"></FilterOption><FilterOption id="15065" count="1" label="Bristol-Myers Squibb Co"></FilterOption><FilterOption id="1120666" count="1" label="Canadian Cancer Trials Group"></FilterOption><FilterOption id="1013107" count="1" label="CNIC - Fundacion Centro National de Investigaciones Cardiovasculares Carlos III"></FilterOption><FilterOption id="1020322" count="1" label="Daiichi Sankyo Inc"></FilterOption><FilterOption id="23119" count="1" label="European Organisation for Research and Treatment of Cancer (EORTC)"></FilterOption><FilterOption id="1042350" count="1" label="Federation Francophone de Cancerologie Digestive"></FilterOption><FilterOption id="1181926" count="1" label="Fundación Sociedad Española de Oncologia Médica"></FilterOption><FilterOption id="27053" count="1" label="Glaxo Group Research Ltd"></FilterOption><FilterOption id="1145220" count="1" label="GlaxoSmithKline Research &amp; Development Ltd"></FilterOption><FilterOption id="28355" count="1" label="GlaxoSmithKline plc"></FilterOption><FilterOption id="1090124" count="1" label="Grupo de Investigación y Divulgación Oncológica"></FilterOption><FilterOption id="1080644" count="1" label="Grupo de Tratamiento de los Tumores Digestivos"></FilterOption><FilterOption id="1047587" count="1" label="Hospital Arnau de Vilanova"></FilterOption><FilterOption id="1079172" count="1" label="Hospital General de Ciudad Real"></FilterOption><FilterOption id="1149835" count="1" label="Idorsia Ltd"></FilterOption><FilterOption id="1042243" count="1" label="International Breast Cancer Study Group"></FilterOption><FilterOption id="1042355" count="1" label="International Collaborative Cancer Group"></FilterOption><FilterOption id="17259" count="1" label="Ipsen"></FilterOption><FilterOption id="17961" count="1" label="Max Delbruck Centrum Fur Molekulare Medizin"></FilterOption><FilterOption id="1037951" count="1" label="North Central Cancer Treatment Group"></FilterOption><FilterOption id="1090120" count="1" label="NOVARTIS (SINGAPORE) PTE LTD"></FilterOption><FilterOption id="23137" count="1" label="Novartis AG"></FilterOption><FilterOption id="1144568" count="1" label="Novartis Pharma Services AG"></FilterOption><FilterOption id="18614" count="1" label="Novo Nordisk A/S"></FilterOption><FilterOption id="1056256" count="1" label="Novotech (Australia) Pty Ltd"></FilterOption><FilterOption id="22006" count="1" label="Pharmacia &amp; Upjohn Inc"></FilterOption><FilterOption id="1182419" count="1" label="Pierre Fabre Iberica, S.A."></FilterOption><FilterOption id="1126288" count="1" label="ROCHE (MALAYSIA) SDN. BHD"></FilterOption><FilterOption id="1009547" count="1" label="Sanofi SA"></FilterOption><FilterOption id="1050186" count="1" label="The TIMI Study Group"></FilterOption><FilterOption id="22487" count="1" label="The University of Hong Kong"></FilterOption><FilterOption id="25439" count="1" label="United Therapeutics Corp"></FilterOption></Filter><Filter label="Last Changed Date By Day" name="trialDateChangeLastByDay" total="37"><FilterOption count="2" label="2009-05-25"></FilterOption><FilterOption count="2" label="2017-02-20"></FilterOption><FilterOption count="2" label="2019-01-24"></FilterOption><FilterOption count="2" label="2019-01-26"></FilterOption><FilterOption count="2" label="2019-03-11"></FilterOption><FilterOption count="1" label="2009-05-27"></FilterOption><FilterOption count="1" label="2014-02-14"></FilterOption><FilterOption count="1" label="2014-09-01"></FilterOption><FilterOption count="1" label="2016-11-16"></FilterOption><FilterOption count="1" label="2016-12-14"></FilterOption><FilterOption count="1" label="2017-07-07"></FilterOption><FilterOption count="1" label="2017-08-04"></FilterOption><FilterOption count="1" label="2017-09-12"></FilterOption><FilterOption count="1" label="2018-03-02"></FilterOption><FilterOption count="1" label="2018-06-11"></FilterOption><FilterOption count="1" label="2018-07-07"></FilterOption><FilterOption count="1" label="2018-07-10"></FilterOption><FilterOption count="1" label="2018-08-02"></FilterOption><FilterOption count="1" label="2018-10-26"></FilterOption><FilterOption count="1" label="2018-11-13"></FilterOption><FilterOption count="1" label="2018-11-19"></FilterOption><FilterOption count="1" label="2018-11-27"></FilterOption><FilterOption count="1" label="2018-11-28"></FilterOption><FilterOption count="1" label="2018-12-06"></FilterOption><FilterOption count="1" label="2019-01-16"></FilterOption><FilterOption count="1" label="2019-01-19"></FilterOption><FilterOption count="1" label="2019-01-25"></FilterOption><FilterOption count="1" label="2019-03-05"></FilterOption><FilterOption count="1" label="2019-04-05"></FilterOption><FilterOption count="1" label="2019-05-02"></FilterOption><FilterOption count="1" label="2019-05-24"></FilterOption><FilterOption count="1" label="2019-05-27"></FilterOption><FilterOption count="1" label="2019-06-03"></FilterOption><FilterOption count="1" label="2019-06-05"></FilterOption><FilterOption count="1" label="2019-06-11"></FilterOption><FilterOption count="1" label="2019-06-27"></FilterOption><FilterOption count="1" label="2019-07-02"></FilterOption></Filter><Filter label="Trial Date End By Month" name="trialDateEndByMonth" total="37"><FilterOption count="2" label="200911"></FilterOption><FilterOption count="2" label="201109"></FilterOption><FilterOption count="2" label="201110"></FilterOption><FilterOption count="2" label="202003"></FilterOption><FilterOption count="1" label="200509"></FilterOption><FilterOption count="1" label="200704"></FilterOption><FilterOption count="1" label="200712"></FilterOption><FilterOption count="1" label="200906"></FilterOption><FilterOption count="1" label="200912"></FilterOption><FilterOption count="1" label="201002"></FilterOption><FilterOption count="1" label="201007"></FilterOption><FilterOption count="1" label="201008"></FilterOption><FilterOption count="1" label="201011"></FilterOption><FilterOption count="1" label="201012"></FilterOption><FilterOption count="1" label="201107"></FilterOption><FilterOption count="1" label="201112"></FilterOption><FilterOption count="1" label="201203"></FilterOption><FilterOption count="1" label="201210"></FilterOption><FilterOption count="1" label="201211"></FilterOption><FilterOption count="1" label="201212"></FilterOption><FilterOption count="1" label="201303"></FilterOption><FilterOption count="1" label="201305"></FilterOption><FilterOption count="1" label="201310"></FilterOption><FilterOption count="1" label="201312"></FilterOption><FilterOption count="1" label="201406"></FilterOption><FilterOption count="1" label="201601"></FilterOption><FilterOption count="1" label="201703"></FilterOption><FilterOption count="1" label="201704"></FilterOption><FilterOption count="1" label="201706"></FilterOption><FilterOption count="1" label="201708"></FilterOption><FilterOption count="1" label="201907"></FilterOption><FilterOption count="1" label="201909"></FilterOption><FilterOption count="1" label="201911"></FilterOption><FilterOption count="1" label="202009"></FilterOption><FilterOption count="1" label="202107"></FilterOption><FilterOption count="1" label="202205"></FilterOption><FilterOption count="1" label="202211"></FilterOption></Filter><Filter label="Trial Date Start By Month" name="trialDateStartByMonth" total="35"><FilterOption count="4" label="200705"></FilterOption><FilterOption count="2" label="200710"></FilterOption><FilterOption count="2" label="201310"></FilterOption><FilterOption count="2" label="201810"></FilterOption><FilterOption count="1" label="199802"></FilterOption><FilterOption count="1" label="199903"></FilterOption><FilterOption count="1" label="199911"></FilterOption><FilterOption count="1" label="200109"></FilterOption><FilterOption count="1" label="200401"></FilterOption><FilterOption count="1" label="200404"></FilterOption><FilterOption count="1" label="200406"></FilterOption><FilterOption count="1" label="200503"></FilterOption><FilterOption count="1" label="200605"></FilterOption><FilterOption count="1" label="200608"></FilterOption><FilterOption count="1" label="200702"></FilterOption><FilterOption count="1" label="200703"></FilterOption><FilterOption count="1" label="200711"></FilterOption><FilterOption count="1" label="200810"></FilterOption><FilterOption count="1" label="200811"></FilterOption><FilterOption count="1" label="200903"></FilterOption><FilterOption count="1" label="200907"></FilterOption><FilterOption count="1" label="200909"></FilterOption><FilterOption count="1" label="201001"></FilterOption><FilterOption count="1" label="201004"></FilterOption><FilterOption count="1" label="201105"></FilterOption><FilterOption count="1" label="201106"></FilterOption><FilterOption count="1" label="201205"></FilterOption><FilterOption count="1" label="201206"></FilterOption><FilterOption count="1" label="201308"></FilterOption><FilterOption count="1" label="201312"></FilterOption><FilterOption count="1" label="201504"></FilterOption><FilterOption count="1" label="201706"></FilterOption><FilterOption count="1" label="201805"></FilterOption><FilterOption count="1" label="201807"></FilterOption><FilterOption count="1" label="201809"></FilterOption></Filter><Filter label="Trial Phase" name="trialPhase" total="8"><FilterOption id="C3" count="16" label="Phase 3 Clinical"></FilterOption><FilterOption id="C2" count="10" label="Phase 2 Clinical"></FilterOption><FilterOption id="PNA" count="7" label="Phase Not Applicable"></FilterOption><FilterOption id="C4" count="4" label="Phase 4 Clinical"></FilterOption><FilterOption id="NS" count="2" label="Phase not specified"></FilterOption><FilterOption id="C12" count="1" label="Phase 1/Phase 2 Clinical"></FilterOption><FilterOption id="C23" count="1" label="Phase 2/Phase 3 Clinical"></FilterOption><FilterOption id="C3B" count="1" label="Phase 3b Clinical"></FilterOption></Filter><Filter label="Inclusion Criteria Index" name="trialInclusionCriteriaIndex" total="100"><FilterOption id="3900" count="12" label="Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)"></FilterOption><FilterOption id="3957" count="11" label="Lung tumor - Subjects Confirmed of Lung Cancer by Specific Modes - Subjects with cytologically/histologically confirmed diagnosis of lung cancer"></FilterOption><FilterOption id="3940" count="10" label="Lung tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="3936" count="10" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IV lung cancer"></FilterOption><FilterOption id="3938" count="9" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with advanced stage lung cancer"></FilterOption><FilterOption id="4032" count="8" label="Lung tumor - Subjects with Protocol Specified Renal Function - Subjects with normal/acceptable renal function"></FilterOption><FilterOption id="4024" count="7" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable liver function"></FilterOption><FilterOption id="3976" count="7" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="3977" count="7" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="3933" count="7" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage III lung cancer"></FilterOption><FilterOption id="4879" count="6" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 0"></FilterOption><FilterOption id="4880" count="6" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 1"></FilterOption><FilterOption id="22381" count="6" label="Lung tumor - Protocol Specified Other Inclusion Criteria - Protocol specified inclusion criteria for females"></FilterOption><FilterOption id="4813" count="5" label="Breast tumor - Subjects with HER-2 Positive Breast Cancer"></FilterOption><FilterOption id="22417" count="5" label="Breast tumor - Subjects with Locally Advanced Cancer/Tumor"></FilterOption><FilterOption id="3953" count="5" label="Lung tumor - Subjects with Co-morbid Conditions - Subjects co-morbid with pleural effusion"></FilterOption><FilterOption id="3935" count="5" label="Lung tumor - Subjects with Protocol Specified Stages of Lung Cancer(TNM staging) - Subjects with stage IIIB lung cancer"></FilterOption><FilterOption id="22418" count="4" label="Breast tumor - Subjects with Early Breast Cancer"></FilterOption><FilterOption id="4893" count="4" label="Breast tumor - Subjects with History of Anti Cancer Therapy"></FilterOption><FilterOption id="22398" count="4" label="Breast tumor - Subjects with Resectable Tumor"></FilterOption><FilterOption id="4824" count="4" label="Breast tumor - TNM Stage II Breast Cancer"></FilterOption><FilterOption id="4073" count="4" label="Lung tumor - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="3989" count="4" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="3971" count="4" label="Lung tumor - Subjects with Protocol Specified Life Expectancy - Subjects with life expectancy of three months or more"></FilterOption><FilterOption id="4106" count="4" label="Lung tumor - Subjects with Protocol Specified Reproductive Status - Men with adequate contraception"></FilterOption><FilterOption id="4000" count="4" label="Lung tumor - Subjects with Relapsed/Recurrent Disease"></FilterOption><FilterOption id="3987" count="4" label="Lung tumor - Treatment Naive Subjects"></FilterOption><FilterOption id="4840" count="3" label="Breast tumor - Subjects with Advanced/Metastatic Cancer"></FilterOption><FilterOption id="4870" count="3" label="Breast tumor - Subjects with History/Scheduled for Surgery/Intervention"></FilterOption><FilterOption id="3913" count="3" label="Lung tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="4041" count="3" label="Lung tumor - Subjects with Normal/Acceptable Organ Function - Subjects with normal/acceptable hematological functions"></FilterOption><FilterOption id="4074" count="3" label="Lung tumor - Subjects with Protocol Specified Compliance Status - Subjects able to comply with the study protocol procedures/ requirements"></FilterOption><FilterOption id="3978" count="3" label="Lung tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="3997" count="3" label="Lung tumor - Subjects with Treatment Resistant Disease"></FilterOption><FilterOption id="3966" count="3" label="Lung tumor - Subjects with Unresectable/In-operable Lung Cancer"></FilterOption><FilterOption id="1335" count="2" label="Acute coronary syndrome - Subjects at Risk of Developing Disease"></FilterOption><FilterOption id="1400" count="2" label="Acute coronary syndrome - Subjects with Dyslipidemia - Subjects with hyperlipidemia"></FilterOption><FilterOption id="1384" count="2" label="Acute coronary syndrome - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="5788" count="2" label="Bipolar disorder - Subjects with Bipolar Disorder - Subjects with bipolar I disorder"></FilterOption><FilterOption id="5862" count="2" label="Bipolar disorder - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of antipsychotic therapy"></FilterOption><FilterOption id="5860" count="2" label="Bipolar disorder - Subjects with History of/Scheduled to Receive Therapy - Subjects with history of mood stabilizer therapy"></FilterOption><FilterOption id="5803" count="2" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with depression"></FilterOption><FilterOption id="5805" count="2" label="Bipolar disorder - Subjects with Symptomatic Disease - Subjects with mania"></FilterOption><FilterOption id="4817" count="2" label="Breast tumor - Postmenopausal Breast Cancer Women"></FilterOption><FilterOption id="4924" count="2" label="Breast tumor - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="4814" count="2" label="Breast tumor - Subjects with HER-2 Negative Breast Cancer"></FilterOption><FilterOption id="4894" count="2" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer chemotherapy"></FilterOption><FilterOption id="4904" count="2" label="Breast tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer radiotherapy"></FilterOption><FilterOption id="4875" count="2" label="Breast tumor - Subjects with History/Scheduled for Surgery/Intervention - Subjects history/scheduled for axillary lymphadenectomy"></FilterOption><FilterOption id="4808" count="2" label="Breast tumor - Subjects with Hormone Receptor Positive Breast Cancer - Estrogen receptor positive (ER+) breast cancer"></FilterOption><FilterOption id="4856" count="2" label="Breast tumor - Subjects with Measurable Disease"></FilterOption><FilterOption id="4881" count="2" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with ECOG/WHO/Zubrod score performance status of 2"></FilterOption><FilterOption id="4885" count="2" label="Breast tumor - Subjects with Protocol Specified Performance Status - Subjects with Karnofsky score of 50 or higher"></FilterOption><FilterOption id="22416" count="2" label="Breast tumor - Subjects with Unresectable Breast Cancer"></FilterOption><FilterOption id="4823" count="2" label="Breast tumor - TNM Stage I Breast Cancer"></FilterOption><FilterOption id="4828" count="2" label="Breast tumor - TNM Stage III Breast Cancer - TNM stage IIIA Breast Cancer"></FilterOption><FilterOption id="4827" count="2" label="Breast tumor - TNM Stage III Breast Cancer"></FilterOption><FilterOption id="3879" count="2" label="Coronary artery disease - Subjects at Risk of Developing Disease - Hyperlipidemia/dyslipidemia"></FilterOption><FilterOption id="1146" count="2" label="Coronary artery disease - Subjects with History of/Scheduled to Receive Therapy - Lipid modifying agents"></FilterOption><FilterOption id="17690" count="2" label="End stage renal disease - Subjects with History of/Scheduled to Receive Therapy"></FilterOption><FilterOption id="17642" count="2" label="End stage renal disease - Subjects with Non-Dialysis Dependant Chronic Kidney Disease(NDD-CKD) - Subjects with stage 3 chronic kidney disease"></FilterOption><FilterOption id="20887" count="2" label="Hypercholesterolemia - Subjects at Risk of Developing Disease - Smoking as a risk factor"></FilterOption><FilterOption id="20894" count="2" label="Hypercholesterolemia - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="20896" count="2" label="Hypercholesterolemia - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20871" count="2" label="Hypercholesterolemia - Subjects with Familial Hypercholesterolemia (Frederickson type IIa Hyperlipoproteinemia) - Subjects with heterozygous familial hypercholesterolemia"></FilterOption><FilterOption id="20901" count="2" label="Hypercholesterolemia - Subjects with History of Lipid Lowering Medication"></FilterOption><FilterOption id="20879" count="2" label="Hypercholesterolemia - Subjects with Increased LDL-cholesterol Levels"></FilterOption><FilterOption id="20878" count="2" label="Hypercholesterolemia - Subjects with Reduced HDL-cholesterol Levels"></FilterOption><FilterOption id="20888" count="2" label="Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease (CHD) - Subjects with diabetes as a risk factor for coronary heart disease"></FilterOption><FilterOption id="20885" count="2" label="Hypercholesterolemia - Subjects with Risk Factors for Coronary Heart Disease (CHD)"></FilterOption><FilterOption id="20866" count="2" label="Hypercholesterolemia - Subjects with specific disease - Subjects with Primary Hypercholesterolemia"></FilterOption><FilterOption id="20033" count="2" label="Lipid metabolism disorder - Subjects at Risk of Developing Disease - Smoking as a risk factor"></FilterOption><FilterOption id="20040" count="2" label="Lipid metabolism disorder - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="20039" count="2" label="Lipid metabolism disorder - Subjects with Co-morbid Conditions"></FilterOption><FilterOption id="20010" count="2" label="Lipid metabolism disorder - Subjects with Dyslipidemia"></FilterOption><FilterOption id="20016" count="2" label="Lipid metabolism disorder - Subjects with Familial Hypercholesterolemia (Frederickson type IIa Hyperlipoproteinemia) - Subjects with heterozygous familial hypercholesterolemia"></FilterOption><FilterOption id="20047" count="2" label="Lipid metabolism disorder - Subjects with History of Lipid Lowering Medication"></FilterOption><FilterOption id="20024" count="2" label="Lipid metabolism disorder - Subjects with Increased LDL-cholesterol Levels"></FilterOption><FilterOption id="20011" count="2" label="Lipid metabolism disorder - Subjects with Primary Hypercholesterolemia"></FilterOption><FilterOption id="20023" count="2" label="Lipid metabolism disorder - Subjects with Reduced HDL-cholesterol Levels"></FilterOption><FilterOption id="20034" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease (CHD) - Subjects with diabetes as a risk factor for coronary heart disease"></FilterOption><FilterOption id="20031" count="2" label="Lipid metabolism disorder - Subjects with Risk Factors for Coronary Heart Disease (CHD)"></FilterOption><FilterOption id="3994" count="2" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of anti-cancer radiotherapy"></FilterOption><FilterOption id="5260" count="2" label="Lung tumor - Subjects with History of Anti Cancer Therapy - Subjects with history of/scheduled for immunotherapy"></FilterOption><FilterOption id="3960" count="2" label="Lung tumor - Subjects with Lung Cancer Expressing Mutations - Subjects with EGFR (epidermal growth factor mutations) mutations"></FilterOption><FilterOption id="3914" count="2" label="Lung tumor - Subjects with Measurable Disease - Subjects with measurable disease as per RECIST criteria"></FilterOption><FilterOption id="32043" count="2" label="Lung tumor - Subjects with Protocol Specified Participation Status - Subjects able/willing to provide written informed consent"></FilterOption><FilterOption id="20767" count="2" label="Menopause - Subjects with Cancer"></FilterOption><FilterOption id="20758" count="2" label="Menopause - Subjects with Protocol Specified Menstrual Status - Postmenopausal subjects"></FilterOption><FilterOption id="13137" count="2" label="Solid tumor - Protocol Specified Other Inclusion Criteria"></FilterOption><FilterOption id="20975" count="2" label="Stroke - Inclusion Based on Angiographic Criteria - Acceptable degree of stenosis"></FilterOption><FilterOption id="20965" count="2" label="Stroke - Subjects at Risk of Developing Disease - Smoking as a risk factor"></FilterOption><FilterOption id="20962" count="2" label="Stroke - Subjects at Risk of Developing Disease - Subjects with dyslipidemia as a risk factor"></FilterOption><FilterOption id="20998" count="2" label="Stroke - Subjects co-morbid with cardiovascular disease/disorder - Subjects with history/scheduled for CABG"></FilterOption><FilterOption id="20997" count="2" label="Stroke - Subjects co-morbid with cardiovascular disease/disorder - Subjects with myocardial infarction"></FilterOption><FilterOption id="20994" count="2" label="Stroke - Subjects co-morbid with cardiovascular disease/disorder"></FilterOption><FilterOption id="21009" count="2" label="Stroke - Subjects co-morbid with renal disease/disorder"></FilterOption><FilterOption id="14364" count="1" label="Anemia - Subjects with Cancer/Cancer Chemotherapy Induced Anemia"></FilterOption><FilterOption id="14414" count="1" label="Anemia - Subjects with Co-morbid Conditions - Subjects co-morbid with premalignant/malignant condition"></FilterOption><FilterOption id="14435" count="1" label="Anemia - Subjects with History of/Scheduled to Receive Therapy"></FilterOption></Filter><Filter label="Trial Interventions Control Alone Name Display" name="trialInterventionsControlAloneNameDisplay" total="8"><FilterOption id="3321" count="1" label="anastrozole"></FilterOption><FilterOption id="8047" count="1" label="bevacizumab"></FilterOption><FilterOption id="11961" count="1" label="erlotinib"></FilterOption><FilterOption id="2871" count="1" label="irinotecan"></FilterOption><FilterOption id="44314" count="1" label="tamoxifen"></FilterOption><FilterOption id="4577" count="1" label="topotecan"></FilterOption><FilterOption id="6386" count="1" label="trastuzumab"></FilterOption><FilterOption id="44375" count="1" label="warfarin"></FilterOption></Filter><Filter label="Trial Actions Primary Interventions Control" name="trialActionsPrimaryInterventionsControl" total="14"><FilterOption id="76" count="1" label="Aromatase inhibitor"></FilterOption><FilterOption id="3754" count="1" label="EGFR family tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="740" count="1" label="Epidermal growth factor receptor antagonist"></FilterOption><FilterOption id="3756" count="1" label="Erbb2 tyrosine kinase receptor inhibitor"></FilterOption><FilterOption id="286" count="1" label="Estrogen receptor antagonist"></FilterOption><FilterOption id="111" count="1" label="Factor IIa antagonist"></FilterOption><FilterOption id="113" count="1" label="Factor IX antagonist"></FilterOption><FilterOption id="114" count="1" label="Factor VII antagonist"></FilterOption><FilterOption id="119" count="1" label="Factor X antagonist"></FilterOption><FilterOption id="23014" count="1" label="Insulin ligand"></FilterOption><FilterOption id="400" count="1" label="Insulin receptor agonist"></FilterOption><FilterOption id="141" count="1" label="Topoisomerase I inhibitor"></FilterOption><FilterOption id="12521" count="1" label="VEGF ligand inhibitor"></FilterOption><FilterOption id="10583" count="1" label="Vitamin K epoxide reductase inhibitor"></FilterOption></Filter><Filter label="Trial Indications Adverse" name="trialIndicationsAdverse" total="72"><FilterOption id="102" count="10" label="Diarrhea"></FilterOption><FilterOption id="226" count="7" label="Nausea"></FilterOption><FilterOption id="829" count="6" label="Fatigue"></FilterOption><FilterOption id="148" count="6" label="Headache"></FilterOption><FilterOption id="3020" count="6" label="Skin rash"></FilterOption><FilterOption id="2439" count="5" label="Arthralgia"></FilterOption><FilterOption id="1991" count="5" label="Neutropenia"></FilterOption><FilterOption id="17" count="4" label="Anemia"></FilterOption><FilterOption id="178" count="4" label="Hypertension"></FilterOption><FilterOption id="3038" count="3" label="Appetite loss"></FilterOption><FilterOption id="552" count="3" label="Bleeding"></FilterOption><FilterOption id="82" count="3" label="Cough"></FilterOption><FilterOption id="110" count="3" label="Emesis"></FilterOption><FilterOption id="750" count="3" label="Insomnia"></FilterOption><FilterOption id="1039" count="3" label="Myalgia"></FilterOption><FilterOption id="3472" count="2" label="Abdominal pain"></FilterOption><FilterOption id="1559" count="2" label="Congestive heart failure"></FilterOption><FilterOption id="3062" count="2" label="Death"></FilterOption><FilterOption id="1835" count="2" label="Epistaxis"></FilterOption><FilterOption id="1833" count="2" label="Fever"></FilterOption><FilterOption id="746" count="2" label="Infectious disease"></FilterOption><FilterOption id="277" count="2" label="Proteinuria"></FilterOption><FilterOption id="1016" count="2" label="Stomatitis"></FilterOption><FilterOption id="2954" count="2" label="Weight gain"></FilterOption><FilterOption id="1996" count="1" label="Akathesia"></FilterOption><FilterOption id="13" count="1" label="Alopecia"></FilterOption><FilterOption id="25" count="1" label="Anxiety disorder"></FilterOption><FilterOption id="3221" count="1" label="Back pain"></FilterOption><FilterOption id="2617" count="1" label="Carpal tunnel syndrome"></FilterOption><FilterOption id="404" count="1" label="Constipation"></FilterOption><FilterOption id="95" count="1" label="Dermatological disease"></FilterOption><FilterOption id="3026" count="1" label="Diabetic ketoacidosis"></FilterOption><FilterOption id="3073" count="1" label="Drowsiness"></FilterOption><FilterOption id="2576" count="1" label="Dysgeusia"></FilterOption><FilterOption id="2400" count="1" label="Dyspnea"></FilterOption><FilterOption id="591" count="1" label="Ear disease"></FilterOption><FilterOption id="402" count="1" label="Edema"></FilterOption><FilterOption id="2024" count="1" label="Erythema"></FilterOption><FilterOption id="3795" count="1" label="Febrile neutropenia"></FilterOption><FilterOption id="2195" count="1" label="Gastroenteritis"></FilterOption><FilterOption id="2184" count="1" label="Gastrointestinal bleeding"></FilterOption><FilterOption id="129" count="1" label="Gastrointestinal disease"></FilterOption><FilterOption id="626" count="1" label="Heart disease"></FilterOption><FilterOption id="628" count="1" label="Hepatobiliary disease"></FilterOption><FilterOption id="2529" count="1" label="Hot flashes"></FilterOption><FilterOption id="505" count="1" label="Hypersensitivity"></FilterOption><FilterOption id="445" count="1" label="Hypoglycemia"></FilterOption><FilterOption id="2733" count="1" label="Hypomagnesemia"></FilterOption><FilterOption id="2466" count="1" label="Interstitial lung disease"></FilterOption><FilterOption id="637" count="1" label="Ischemia"></FilterOption><FilterOption id="680" count="1" label="Leukopenia"></FilterOption><FilterOption id="655" count="1" label="Metabolic disorder"></FilterOption><FilterOption id="3463" count="1" label="Metastatic CNS cancer"></FilterOption><FilterOption id="1263" count="1" label="Mucositis"></FilterOption><FilterOption id="216" count="1" label="Musculoskeletal disease"></FilterOption><FilterOption id="2134" count="1" label="Nail disease"></FilterOption><FilterOption id="677" count="1" label="Neurological disease"></FilterOption><FilterOption id="678" count="1" label="Neuropathy"></FilterOption><FilterOption id="1089" count="1" label="Neurotoxicity drug-induced"></FilterOption><FilterOption id="684" count="1" label="Nutritional disorder"></FilterOption><FilterOption id="246" count="1" label="Osteoporosis"></FilterOption><FilterOption id="20" count="1" label="Pain"></FilterOption><FilterOption id="259" count="1" label="Peripheral neuropathy"></FilterOption><FilterOption id="360" count="1" label="Pneumonia"></FilterOption><FilterOption id="3195" count="1" label="Reproductive disorder"></FilterOption><FilterOption id="288" count="1" label="Retinopathy"></FilterOption><FilterOption id="114" count="1" label="Sepsis"></FilterOption><FilterOption id="65" count="1" label="Stroke"></FilterOption><FilterOption id="3117" count="1" label="Suicidal ideation"></FilterOption><FilterOption id="324" count="1" label="Thrombocytopenia"></FilterOption><FilterOption id="325" count="1" label="Thromboembolism"></FilterOption><FilterOption id="742" count="1" label="Vascular disease"></FilterOption></Filter></Filters><SearchResults><Trial Id="97508"><Indications><Indication>Metastatic non small cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-09-12T00:00:00Z</DateChangeLast><DateEnd>2017-06-20T00:00:00Z</DateEnd><DateStart>2013-12-30T00:00:00Z</DateStart><Identifiers><Identifier>ASPET Study</Identifier><Identifier>ML28361</Identifier><Identifier>NCT01723878</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>erlotinib alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>144</PatientCountEnrollment><Phase>Phase 4 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The purpose of this observational study was to evaluate the patterns of disease progression in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) activating mutations receiving Tarceva ( erlotinib ) as first-line treatment.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Disease Progression - Assessment of time to disease progression (TTP)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Mortality/Death Rates</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Objective Response - Assessment of objective response rate(ORR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS) - Assessment of global/overall survival at 1 year</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Pharmacokinetic/Pharmacodynamic Parameters</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of Other Treatment Related Outcomes</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>ASPET Study: An Observational Study of Tarceva (Erlotinib) in First-Line in Patients With Advanced Non-Small Cell Lung Cancer Harboring EGFR Activating Mutations</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with EGFR Positive Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with gene variants - EGFR_HUMAN_Mutation(GOF)</PatientSegment><PatientSegment>Lung tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Epidermal growth factor receptor</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2017-06-20T00:00:00Z</PrimaryCompletionDate><TrialDuration>41 Months</TrialDuration><NumberOfSites>43</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="86279"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Epidermal growth factor receptor antagonist</Action><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action><Action>Microtubule stabilizer</Action><Action>Synergist</Action><Action>Vasoprotectant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Liquid formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Nanoparticle formulation injectable</Technology><Technology>Natural product</Technology><Technology>Pharmaceutical carrier</Technology><Technology>Protein conjugated</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Suspension</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company></CompaniesSponsor><Countries><Country>Pakistan</Country><Country>Portugal</Country><Country>Hungary</Country><Country>Germany</Country><Country>Uruguay</Country><Country>Vietnam</Country><Country>Ukraine</Country><Country>Hong Kong</Country><Country>Turkey</Country><Country>South Africa</Country><Country>Brazil</Country><Country>Thailand</Country><Country>Asia</Country><Country>Venezuela</Country><Country>Costa Rica</Country><Country>South America</Country><Country>France</Country><Country>Lithuania</Country><Country>United Arab Emirates</Country><Country>Algeria</Country><Country>Saudi Arabia</Country><Country>Italy</Country><Country>Spain</Country><Country>Israel</Country><Country>Sweden</Country><Country>Morocco</Country><Country>Kuwait</Country><Country>Peru</Country><Country>UK</Country><Country>China</Country><Country>Australia</Country><Country>Lebanon</Country><Country>Colombia</Country><Country>Belgium</Country><Country>Greece</Country><Country>Singapore</Country><Country>Qatar</Country><Country>Japan</Country><Country>Poland</Country><Country>Austria</Country><Country>Finland</Country><Country>Philippines</Country><Country>Argentina</Country><Country>Egypt</Country><Country>Chile</Country><Country>Mexico</Country><Country>India</Country><Country>Russian Federation</Country><Country>Europe</Country><Country>Netherlands</Country><Country>Serbia</Country><Country>Ecuador</Country><Country>Slovenia</Country><Country>Canada</Country><Country>Indonesia</Country><Country>Bahrain</Country><Country>Estonia</Country><Country>Africa</Country></Countries><DateChangeLast>2019-05-24T00:00:00Z</DateChangeLast><DateEnd>2019-09-28T00:00:00Z</DateEnd><DateStart>2012-06-01T00:00:00Z</DateStart><Identifiers><Identifier>11574</Identifier><Identifier>2011-005334-20</Identifier><Identifier>CTR20130952</Identifier><Identifier>JXSL1200006</Identifier><Identifier>MO28047</Identifier><Identifier>NCT01572038</Identifier><Identifier>PERUSE</Identifier></Identifiers><IndicationsAdverse><Indication>Abdominal pain</Indication><Indication>Alopecia</Indication><Indication>Anemia</Indication><Indication>Appetite loss</Indication><Indication>Arthralgia</Indication><Indication>Cough</Indication><Indication>Death</Indication><Indication>Diarrhea</Indication><Indication>Dysgeusia</Indication><Indication>Dyspnea</Indication><Indication>Edema</Indication><Indication>Emesis</Indication><Indication>Epistaxis</Indication><Indication>Erythema</Indication><Indication>Fatigue</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Hypersensitivity</Indication><Indication>Metastatic CNS cancer</Indication><Indication>Myalgia</Indication><Indication>Nail disease</Indication><Indication>Nausea</Indication><Indication>Neurotoxicity drug-induced</Indication><Indication>Neutropenia</Indication><Indication>Peripheral neuropathy</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>Variable regimens including docetaxel , docetaxel + paclitaxel + Abraxane , paclitaxel , paclitaxel (albumin-bound nanoparticle, intravenous), Celgene , pertuzumab , trastuzumab</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>1436</PatientCountEnrollment><Phase>Phase 3b Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This multicenter, open-label, single-arm, Phase IIIb study was to evaluate the safety and tolerability of pertuzumab in combination with trastuzumab (Herceptin) and a taxane in first-line treatment in patients with metastatic or locally recurrent HER2-positive breast cancer [ 1562342 ]. Main objective of the trial was to evaluate the safety and tolerability of pertuzumab in combination with trastuzumab and a taxane. Secondary objectives of the trial were: To evaluate pertuzumab in combination</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of duration of tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of time to tumor response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments - Assessment by FACT - Breast Cancer (FACT-B)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>PERUSE: A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Relapsed/Recurrent Breast cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Un-resectable/Non-operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Ejection fraction </BiomarkerName><BiomarkerName> HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Neutrophils</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Anticipated">2019-09-28T00:00:00Z</PrimaryCompletionDate><TrialDuration>87 Months</TrialDuration><NumberOfSites>753</NumberOfSites><ContactNames><Name>Clinical Operations</Name><Name>Clinical Trials</Name><Name>David Miles</Name><Name>HU Xi-chun</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="86076"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action><Action>Hyaluronidase stimulator</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Drug combination</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Recombinant enzyme</Technology><Technology>Subcutaneous formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company><Company>ROCHE (MALAYSIA) SDN. BHD</Company><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Russian Federation</Country><Country>Greece</Country><Country>UK</Country><Country>France</Country><Country>Spain</Country><Country>Colombia</Country><Country>Ecuador</Country><Country>Pakistan</Country><Country>Slovenia</Country><Country>Trinidad and Tobago</Country><Country>Tunisia</Country><Country>Venezuela</Country><Country>Bahrain</Country><Country>Albania</Country><Country>Australia</Country><Country>Argentina</Country><Country>Panama</Country><Country>Sweden</Country><Country>Ukraine</Country><Country>Germany</Country><Country>South Korea</Country><Country>Brazil</Country><Country>Philippines</Country><Country>Dominican Republic</Country><Country>Mexico</Country><Country>El Salvador</Country><Country>Norway</Country><Country>Lithuania</Country><Country>Montenegro</Country><Country>Bulgaria</Country><Country>Uruguay</Country><Country>Lebanon</Country><Country>Peru</Country><Country>Finland</Country><Country>Taiwan</Country><Country>Turkey</Country><Country>Netherlands</Country><Country>United Arab Emirates</Country><Country>Switzerland</Country><Country>Egypt</Country><Country>Thailand</Country><Country>Europe</Country><Country>Vietnam</Country><Country>India</Country><Country>Hungary</Country><Country>Portugal</Country><Country>Malaysia</Country><Country>Czech Republic</Country><Country>Poland</Country><Country>Kuwait</Country><Country>Indonesia</Country><Country>Qatar</Country><Country>Croatia</Country><Country>Moldova, Republic of</Country><Country>Singapore</Country><Country>Italy</Country><Country>Canada</Country><Country>Guatemala</Country><Country>Algeria</Country><Country>Hong Kong</Country><Country>Serbia</Country><Country>New Zealand</Country><Country>Ireland</Country><Country>South Africa</Country><Country>Slovakia</Country><Country>Romania</Country><Country>Chile</Country><Country>Bosnia and Herzegovina</Country><Country>Morocco</Country><Country>Saudi Arabia</Country></Countries><DateChangeLast>2019-06-11T00:00:00Z</DateChangeLast><DateEnd>2020-03-03T00:00:00Z</DateEnd><DateStart>2012-05-17T00:00:00Z</DateStart><Identifiers><Identifier>10569</Identifier><Identifier>2011-005328-17</Identifier><Identifier>DRKS00004499</Identifier><Identifier>MO28048</Identifier><Identifier>MO28048 10569</Identifier><Identifier>NCT01566721</Identifier><Identifier>NMRR-11-1020-10569</Identifier><Identifier>SafeHER</Identifier></Identifiers><IndicationsAdverse><Indication>Arthralgia</Indication><Indication>Congestive heart failure</Indication><Indication>Cough</Indication><Indication>Diarrhea</Indication><Indication>Fever</Indication><Indication>Headache</Indication><Indication>Heart disease</Indication><Indication>Myalgia</Indication><Indication>Nausea</Indication><Indication>Skin rash</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>trastuzumab + hyaluronidase (breast cancer, Enhanze), Roche/Halozyme alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>2577</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>No longer recruiting</RecruitmentStatus><Teaser>This multicenter, two-cohort, non-randomized, open-label study would evaluate the safety and tolerability of assisted and self-administered Herceptin SC as adjuvant therapy in patients with early HER2-positive breast cancer following tumor excision. Anticipated time on study treatment was up to one year [ 1496860 ]. Main objective of the trial was: to assess the overall safety and tolerability of Herceptin SC in HER2-positive early breast cancer (EBC) patients with assisted administration using a</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Free Survival (DFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex><EndpointIndex>Breast tumor - Patient Reported Outcomes/Quality of Life Assessments</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>SafeHER: A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Early Stage Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Locally Advanced Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Resectable/Operable Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage I Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage II Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with Stage III Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Left ventricular ejection fraction </BiomarkerName><BiomarkerName> Total body mass</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2015-03-10T00:00:00Z</PrimaryCompletionDate><TrialDuration>93 Months</TrialDuration><NumberOfSites>1032</NumberOfSites><ContactNames><Name>Beena Devi CR</Name><Name>Clinical Trials</Name><Name>Dr Flora Chong Li Tze</Name><Name>Dr LEE WEI CHING</Name><Name>Dr Teoh Choon Yu</Name><Name>Dr. Beena Devi.C.R</Name><Name>Ethics &amp; Administrative Trial Unit</Name><Name>Ms Cheong Jin Ni</Name><Name>Raymond Ng Chee Hui</Name><Name>Sheikh Mohammad Norhafiz Bin Abdul Aziz</Name><Name>Stephen Suresh A/L Santiago George</Name><Name>Ter Yow Wei</Name><Name>Trial Information Support Line-TISL</Name></ContactNames></Trial><Trial Id="80762"><Indications><Indication>Breast tumor</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Erbb2 tyrosine kinase receptor inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Anticancer monoclonal antibody</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Apoptosis stimulator</Action><Action>Cell cycle inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Formulation powder</Technology><Technology>Freeze drying</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology></Technologies><CompaniesCollaborator><Company>Roche Holding AG</Company></CompaniesCollaborator><CompaniesSponsor><Company>Asociacion para el Progreso de la Oncologia en Malaga</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-20T00:00:00Z</DateChangeLast><DateEnd>2011-09-01T00:00:00Z</DateEnd><DateStart>2009-09-30T00:00:00Z</DateStart><Identifiers><Identifier>LongHer</Identifier><Identifier>LongHer</Identifier><Identifier>NCT01433926</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>trastuzumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>114</PatientCountEnrollment><Phase>Phase Not Applicable</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The main objective of this study was to analyze the clinical and biological characteristics of patients with disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete remission, partial or stable disease for a period exceeding three years. In addition, there would be a sub-genetic analysis of patients in whom there is availability of a sample of primary tumor preserved in paraffin. The secondary objectives were to: Determine the frequency of patients achieving partial</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cross-sectional</Term><Term>Case Control</Term></TermsDesign><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Hormone Levels</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Safety and Tolerability - Assessment of treatment induced toxicity</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Female</Term><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>LongHer: Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete, Partial Remission or Stabilization of Disease During More Than Three Years</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with HER-2 Positive Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with gene variants - ERBB2_HUMAN_Amplification</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2011-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>23 Months</TrialDuration><NumberOfSites>39</NumberOfSites><ContactNames><Name>Emilio Alba</Name></ContactNames></Trial><Trial Id="77598"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2017-02-20T00:00:00Z</DateChangeLast><DateEnd>2012-11-30T00:00:00Z</DateEnd><DateStart>2011-05-31T00:00:00Z</DateStart><Identifiers><Identifier>ML25493</Identifier><Identifier>NCT01358942</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>156</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This prospective, observational study would evaluate the evolution of lung cancer related symptoms and their correlation with the disease control rate (complete response, partial response and stable disease) in patients with non-small-cell lung cancer initiating first-line treatment with standard platinum-based chemotherapy with or without bevacizumab . Data would be collected from each patient at baseline and after four to six cycles of chemotherapy.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Prospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Clinical Symptoms - Symptom assessment by lung cancer symptom scale (LCSS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Complete Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Partial Response (PR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Stable Disease</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Imaging/Radiological Assessments - Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study of Lung Cancer Related Symptoms and Disease Control Rate in Patients With Non-Small-Cell Lung Cancer Receiving First-Line Platinum-Based Chemotherapy With or Without Avastin (Bevacizumab)</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Treatment Naive Subjects</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-11-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>18 Months</TrialDuration><NumberOfSites>38</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="76940"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Protein recombinant</Technology><Technology>Solution</Technology></Technologies><CompaniesSponsor><Company>Roche Holding AG</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2016-12-14T00:00:00Z</DateChangeLast><DateEnd>2011-12-31T00:00:00Z</DateEnd><DateStart>2011-06-30T00:00:00Z</DateStart><Identifiers><Identifier>ML25494</Identifier><Identifier>NCT01343914</Identifier></Identifiers><InterventionsPrimaryDisplay><Intervention>bevacizumab alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>118</PatientCountEnrollment><Phase>Phase not specified</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This retrospective, observational study analyzed demographical, clinical and treatment-related data of patients with non-squamous non-small cell lung cancer (NSCLC) who had reached &gt;/= 9 months of progression-free survival after Avastin ( bevacizumab )-based first-line therapy. Data was collected for approximately 9 months.</Teaser><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Observational</Term><Term>Cohort</Term><Term>Retrospective</Term></TermsDesign><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>An Observational Study on Patients With Non-Squamous, Non-Small Cell Lung Cancer Who Reached A Long Progression Free Survival After Avastin (Bevacizumab)-Based First-Line Therapy</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC) - Subjects with non-squamous cell lung cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2011-12-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>6 Months</TrialDuration><NumberOfSites>35</NumberOfSites><ContactNames><Name>Clinical Trials</Name></ContactNames></Trial><Trial Id="66319"><Indications><Indication>Bipolar I disorder</Indication><Indication>Depression</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Dopamine transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Psychostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cephalon Inc</Company></CompaniesSponsor><Countries><Country>Australia</Country><Country>Finland</Country><Country>India</Country><Country>Germany</Country><Country>South Africa</Country><Country>Czech Republic</Country><Country>Ukraine</Country><Country>Spain</Country><Country>Croatia</Country><Country>Brazil</Country><Country>Hungary</Country><Country>Slovakia</Country><Country>Serbia</Country><Country>Poland</Country><Country>France</Country><Country>Argentina</Country><Country>Italy</Country><Country>Bulgaria</Country><Country>Canada</Country><Country>US</Country></Countries><DateChangeLast>2018-12-06T00:00:00Z</DateChangeLast><DateEnd>2013-10-31T00:00:00Z</DateEnd><DateStart>2010-04-30T00:00:00Z</DateStart><Identifiers><Identifier>2009-016648-38</Identifier><Identifier>C10953/3074</Identifier><Identifier>NCT01121536</Identifier><Identifier>SACT_1219</Identifier></Identifiers><IndicationsAdverse><Indication>Akathesia</Indication><Indication>Anxiety disorder</Indication><Indication>Drowsiness</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Weight gain</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>armodafinil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>867</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of this study was to evaluate the safety and tolerability of long-term (6 months) armodafinil treatment as adjunctive therapy to mood-stabilizing medications in adults with bipolar I disorder whose most recent episode was a depressive episode. Secondary objectives of the trial were as follows: To evaluate long-term efficacy of armodafinil treatment as adjunctive therapy for adults who are experiencing a major depressive episode associated with bipolar I disorder, as assessed</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Non-Randomized</Term><Term>Open Label</Term><Term>No Control</Term><Term>Single Group Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Anxiety by Protocol Specified Scales - Assessment by Hamilton Anxiety Rating Scale (HAM-A)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Cardiac Function</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Quick Inventory Depressive Symptoms (QIDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Manic Symptoms by Specific Scales - Assessment by Young Mania Rating Scale (YMRS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Physical Examination</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Sleep</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Vital Signs</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of adverse events</EndpointIndex><EndpointIndex>Bipolar disorder - Patient Reported Outcomes/Quality of Life Assessments - Assessment by Columbia Suicide Severity Rating Scale (CSSR-S)</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>Extension Study of the Safety and Efficacy of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>Alanine transaminase </BiomarkerName><BiomarkerName> Aspartate aminotransferase </BiomarkerName><BiomarkerName> Blood platelets </BiomarkerName><BiomarkerName> Diastolic blood pressure </BiomarkerName><BiomarkerName> Heart rate </BiomarkerName><BiomarkerName> Hematocrit </BiomarkerName><BiomarkerName> Hemoglobin </BiomarkerName><BiomarkerName> Leukocyte count </BiomarkerName><BiomarkerName> Neutrophils </BiomarkerName><BiomarkerName> Systolic blood pressure </BiomarkerName><BiomarkerName> Total body mass </BiomarkerName><BiomarkerName> Urea nitrogen </BiomarkerName><BiomarkerName> Uric acid </BiomarkerName><BiomarkerName> gamma-Glutamyltransferase</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2013-10-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>42 Months</TrialDuration><NumberOfSites>292</NumberOfSites><ContactNames><Name>Margui Chia</Name><Name>Sponsor's Medical Expert</Name></ContactNames></Trial><Trial Id="64395"><Indications><Indication>Bipolar I disorder</Indication><Indication>Major depressive disorder</Indication></Indications><ActionsPrimaryInterventionsPrimary><Action>Alpha 1 adrenoceptor agonist</Action><Action>Dopamine transporter inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsPrimary><Action>Psychostimulant</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Stereochemistry</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesCollaborator><Company>Teva Pharmaceutical Industries Ltd</Company></CompaniesCollaborator><CompaniesSponsor><Company>Cephalon Inc</Company></CompaniesSponsor><Countries><Country>Bulgaria</Country><Country>France</Country><Country>Poland</Country><Country>Canada</Country><Country>Serbia</Country><Country>Spain</Country><Country>Australia</Country><Country>Argentina</Country><Country>US</Country><Country>Ukraine</Country><Country>Romania</Country></Countries><DateChangeLast>2018-11-19T00:00:00Z</DateChangeLast><DateEnd>2012-03-31T00:00:00Z</DateEnd><DateStart>2010-01-31T00:00:00Z</DateStart><Identifiers><Identifier>2009-016667-11</Identifier><Identifier>C10953/3071</Identifier><Identifier>NCT01072929</Identifier></Identifiers><IndicationsAdverse><Indication>Diarrhea</Indication><Indication>Headache</Indication><Indication>Insomnia</Indication><Indication>Nausea</Indication><Indication>Suicidal ideation</Indication></IndicationsAdverse><InterventionsPrimaryDisplay><Intervention>armodafinil alone</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>433</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>The primary objective of the study was to determine whether armodafinil treatment, at dosages of 150 and 200 mg/day, was more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of adult subjects with major depression associated with bipolar I disorder. The main objective of the study was to determine whether armodafinil treatment, at a dosage of 150mg/day, is more effective than placebo treatment as adjunctive therapy to mood stabilizers for treatment of</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Placebo Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term><Term>Pharmacodynamics</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Depression Severity by Specific Criteria - Assessment by Inventory Depressive Symptomatology (IDS)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Functional Disability/Physical Function - Assessment of subjects by Global Assessment of Functioning Scale (GAF)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Neuropsychological Function - Assessment by Clinical Global Impression (CGI)</EndpointIndex><EndpointIndex>Bipolar disorder - Assessment of Safety and Tolerability</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term></TermsPatientSelection><TitleDisplay>A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder</TitleDisplay><PatientSegmentTerms><PatientSegment>Bipolar disorder - Subjects with Bipolar I Disorder</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Actual">2012-03-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>26 Months</TrialDuration><NumberOfSites>105</NumberOfSites><ContactNames><Name>Sponsor's Medical Expert</Name></ContactNames></Trial><Trial Id="58318"><Indications><Indication>Metastatic breast cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>Thymidylate synthase inhibitor</Action><Action>VEGF ligand inhibitor</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer monoclonal antibody</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Angiogenesis inhibitor</Action><Action>Anti-inflammatory</Action><Action>Anticancer</Action><Action>Anticancer antimetabolite</Action><Action>Anticancer monoclonal antibody</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Biological therapeutic</Technology><Technology>Film coating</Technology><Technology>Immunoglobulin-G</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Monoclonal antibody humanized</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Orally disintegrating tablet</Technology><Technology>Prodrug</Technology><Technology>Protein recombinant</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>F Hoffmann-La Roche AG</Company></CompaniesSponsor><Countries><Country>China</Country><Country>France</Country><Country>Spain</Country><Country>Egypt</Country><Country>Brazil</Country><Country>India</Country><Country>Hong Kong</Country><Country>Italy</Country><Country>Saudi Arabia</Country><Country>Turkey</Country><Country>Poland</Country></Countries><DateChangeLast>2017-07-07T00:00:00Z</DateChangeLast><DateEnd>2014-06-30T00:00:00Z</DateEnd><DateStart>2009-07-31T00:00:00Z</DateStart><Identifiers><Identifier>2008-006872-31</Identifier><Identifier>CTR20131087</Identifier><Identifier>CTRI/2009/091/000423</Identifier><Identifier>IMELDA</Identifier><Identifier>MO22223</Identifier><Identifier>NCT00929240</Identifier></Identifiers><IndicationsAdverse><Indication>Gastroenteritis</Indication><Indication>Hypertension</Indication><Indication>Proteinuria</Indication></IndicationsAdverse><InterventionsControlDisplay><Intervention>bevacizumab alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>Variable regimens including Xeloda + Avastin , bevacizumab , capecitabine , docetaxel</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>287</PatientCountEnrollment><Phase>Phase 3 Clinical</Phase><RecruitmentStatus>Completed</RecruitmentStatus><Teaser>This randomized study was to compare maintenance therapy with Avastin (bevacizumab) plus Xeloda (capecitabine) versus Avastin alone, in patients with HER2-negative metastatic breast cancer who have not progressed during first-line therapy with docetaxel plus Avastin [ 1494889 ]. The study was to assess whether adding Xeloda to maintenance Avastin continued until disease progression (PD) after initial Avastin plus Xeloda improves progression-free survival (PFS) [ 1596254 ].</Teaser><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Breast tumor - Assessment of Disease Progression - Assessment of Time to Tumor Progression (TTP)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Laboratory/Diagnostic Measures</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Clinical Benefit Rate (CBR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of Response Rates (RR) - Assessment of Overall/Objective Response Rate (ORR)</EndpointIndex><EndpointIndex>Breast tumor - Assessment of adverse events</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>IMELDA: A Study of Avastin (Bevacizumab) + Xeloda (Capecitabine) as Maintenance Therapy in Patients With HER2-Negative Metastatic Breast Cancer</TitleDisplay><PatientSegmentTerms><PatientSegment>Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer</PatientSegment><PatientSegment>Breast tumor - Subjects with HER-2 Negative Breast Cancer</PatientSegment></PatientSegmentTerms><BiomarkerNames><BiomarkerName>HER2 </BiomarkerName><BiomarkerName> Urinary protein</BiomarkerName></BiomarkerNames><PrimaryCompletionDate type="Actual">2014-06-30T00:00:00Z</PrimaryCompletionDate><TrialDuration>59 Months</TrialDuration><NumberOfSites>67</NumberOfSites><ContactNames><Name>Clinical Trials</Name><Name>Jiang Zefei</Name><Name>Li Jing</Name></ContactNames></Trial><Trial Id="56228"><Indications><Indication>Non-small-cell lung cancer</Indication></Indications><ActionsPrimaryInterventionsControl><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsControl><ActionsPrimaryInterventionsPrimary><Action>EGFR family tyrosine kinase receptor inhibitor</Action><Action>Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><ActionsSecondaryInterventionsControl><Action>Anticancer protein kinase inhibitor</Action></ActionsSecondaryInterventionsControl><ActionsSecondaryInterventionsPrimary><Action>Anticancer</Action><Action>Anticancer protein kinase inhibitor</Action><Action>Cell cycle inhibitor</Action><Action>Microtubule inhibitor</Action></ActionsSecondaryInterventionsPrimary><Technologies><Technology>Film coating</Technology><Technology>Infusion</Technology><Technology>Intravenous formulation</Technology><Technology>Natural product</Technology><Technology>Oral formulation</Technology><Technology>Small molecule therapeutic</Technology><Technology>Solution</Technology><Technology>Tablet formulation</Technology></Technologies><CompaniesSponsor><Company>Hospital Arnau de Vilanova</Company></CompaniesSponsor><Countries><Country>Spain</Country></Countries><DateChangeLast>2009-05-27T00:00:00Z</DateChangeLast><DateEnd>2010-12-31T00:00:00Z</DateEnd><DateStart>2009-03-31T00:00:00Z</DateStart><Identifiers><Identifier>ML25033</Identifier><Identifier>NCT00908336</Identifier></Identifiers><InterventionsControlDisplay><Intervention>erlotinib alone</Intervention></InterventionsControlDisplay><InterventionsPrimaryDisplay><Intervention>docetaxel plus erlotinib</Intervention></InterventionsPrimaryDisplay><PatientCountEnrollment>70</PatientCountEnrollment><Phase>Phase 2 Clinical</Phase><RecruitmentStatus>Recruiting</RecruitmentStatus><Teaser>This study will investigate if the intermittent treatment of a chemotherapy drug, such as docetaxel , with erlotinib could achieve a clinical benefit.</Teaser><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Interventional</Term><Term>Treatment</Term><Term>Randomized</Term><Term>Open Label</Term><Term>Active Control</Term><Term>Parallel Assignment</Term></TermsDesign><TermsEndpoint><Term>Safety</Term><Term>Efficacy</Term></TermsEndpoint><EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Overall Survival (OS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Progression Free Survival (PFS) - Assessment of progression free survival at 6 months</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of Tumor Growth Control Rate (TGCR)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of clinical response rate</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Response Rates (RR) - Assessment of duration of response</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of frequency and severity of adverse events</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Safety and Tolerability - Assessment of gastrointestinal toxicities (Upper and Lower)</EndpointIndex><EndpointIndex>Lung tumor - Assessment of Survival - Assessment of median survival</EndpointIndex><EndpointIndex>Lung tumor - Protocol Specified Other Endpoints - Assessment of dermatologic manifestations</EndpointIndex></EndpointIndex><TermsPatientSelection><Term>Young Adults (18-44 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TitleDisplay>Erlotinib and Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Failure of One Chemotherapy Regimen</TitleDisplay><PatientSegmentTerms><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with locally advanced/stage III lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer</PatientSegment><PatientSegment>Lung tumor - Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment><PatientSegment>Lung tumor - Subjects with Treatment Resistant Disease</PatientSegment><PatientSegment>Lung tumor - Subjects with Unresectable/In-operable Lung Cancer</PatientSegment></PatientSegmentTerms><PrimaryCompletionDate type="Anticipated">2010-08-31T00:00:00Z</PrimaryCompletionDate><TrialDuration>21 Months</TrialDuration><NumberOfSites>8</NumberOfSites><ContactNames><Name>Alfredo Sánchez, Doctor</Name><Name>Alfreso Sánchez, Doctor</Name><Name>Antonio López, Doctor</Name><Name>Francisco Aparisi, Doctor</Name><Name>Gaspar Esquerdo, Doctor</Name><Name>José Muñoz, Doctor</Name><Name>Oscar Juan, Doctor</Name><Name>Sonia Maciá, Doctor</Name><Name>Vicente Alberola, Doctor</Name><Name>Vicente Giner, Doctor</Name></ContactNames></Trial></SearchResults></ns2:com.thomsonreuters.ls.service.contract.soap.trials.v2.TrialResultsOutput>